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Abstract
Adherence to antiretroviral medicines is essential to halt human immunodeficiency virus
progression, increase CD4 counts, decrease virologic impact, and improve quality of life
for the infected people. However, sustaining good adherence among adolescents and
young adults (AYA) has been a challenge caused by various problems such as distance to
clinic, improved CD4 count which lead to complacency in adherence, and the nature of
the environment. This was a quantitative, retrospective, correlational, cross-sectional
study anchored by the transtheoretical model, which was used to understand how
adherence rate among the study population was impacted by the predictive factors.
Secondary data was collected from patient’s medical records at the Federal Medical
Center, Makurdi in Benue State, Nigeria. Univariate analysis was conducted using
descriptive statistics. The study sample size of 656 patients was drawn from AYA ages
15–24 years. Independent t tests showed a statistically significant difference in adherence
rates between rural (94%) and urban (89%) AYA, t (424) = -3.280, p = 001. There was
also a statistically significant difference in adherence rates of ART for patients who lived
within 50 kilometers of the hospital and those who lived more than 50 kilometers away
from the hospital, t (509) = -2.37, p = .018. Also, there was a statistically significant
correlation between adherence rate to ART and CD4 of less than 500 cells/mm3, R =
.214, p = .003. This study provides findings for HIV implementing partners (IPs) and
relevant health professionals in Nigeria useful for designing strategies that would
improve adherence rate to antiretroviral therapy among AYA in Nigeria.
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Chapter 1: Introduction to the Study
Introduction
Human Immunodeficiency Virus (|HIV) remains a pandemic that has claimed
many lives and has impacted the healthcare systems of many countries, especially those
in developing nations (Volberding, 2011). The advent of effective Antiretroviral (ARV)
medicines has changed the landscape of medical intervention in HIV, which is now
considered a chronic illness (Groh et al., 2011; Tougas, Hayden, McGrath, Huguet, &
Rozario, 2015). One useful strategy in the management of the HIV virus is ensuring
patients’ good adherence to ARVARVs. The ARVs work better when there is adherence
to the treatment, which goes beyond the act of taking the ARV to include the individual’s
attitude towards treatment (Jimmy, Jose Beena Jimmy, & Jose, 2011; Viswanathan et al.,
2015).
In this study, I focused on adherence to ARV medicines among AYA in Benue
State, Nigeria. My emphasis was on how adherence to ARV relates to (a) distance from
patient’s place of residence to the HIV treatment center, (b) environment where patient
lives (urban versus rural) (c) low CD4 (less than 500 cells/mm3) and high CD4 (more
than 500 cells/mm3). Adherence to ARV medicines is essential in the management of
HIV infection (World Health Organization, 2015). There is a plethora of ARVs used in
the cocktail to manage HIV, but these drug combinations give the desired therapeutic
result only when patients are adherent to the medicines. Understanding covariates of
adherence to ARVs would help the various HIV implementing partners (IPs) working in
conjunction with the Federal Ministry of Health (FMoH) in Nigeria to make a shift in
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how patients are enrolled into care, and in how measures are transformed to enhance
adherence among HIV patients in care. Findings from this study could provide a basis for
the HIV IPs in Nigeria to encourage HIV clients to enroll for treatment in treatment
centers proximal to their place of residence. A positive correlation between adherence
and high CD4 counts would help adherence counselors reinforce adherence counselling
continually for clients instead of the common practice of focusing on new enrollees.
In Chapter 1, I offer a brief overview of HIV infection in Nigeria and offer the
problem statement. Next, I present the researcher questions and discuss the theoretical
framework. I then highlight the assumptions I made in the research, and discuss the
scope, delimitation, and limitations of the research. The chapter ends with a discussion of
the significance of the study and summary of the chapter.
Background of the Study
According to the World Development Indicator, in 2013, per capital GDP in
Nigeria was only $2,980, ranking it 131st in the world (Ajakaiye, Jerome, Nabena, &
Alabi A. Olufunke, 2015). The country is categorized as among the low- and mediumincome countries. The first diagnosis of HIV in Nigeria was in Lagos in 1986. The
following years saw numbers jump dramatically with two reported cases in 1987, 33 in
1988, and 9715 in the year 2000. At the onset of HIV in the country, there was a lot of
skepticism about whether the disease was real or a mere ploy by the Western world to
discourage sex and limit the perceived growth of African populations (Zeleza & Kakoma,
2003). Such skeptics even dubbed the acronym as “American idea of discouraging sex”
(AIDS). Before the first sentinel survey in Nigeria, the prevalence of HIV was on a
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steady rise. It was 1.8% in 1991, 3.8% in 1993, 5.4% in 1999, and 5.8% in 2001
(National Agency for the Control of AIDS (NACA), 2015). In 2011, with an estimated
population of 180 million people, Nigeria had HIV prevalence rate of 3.3% (Bashorun et
al., 2014). In 2015, the country had a projected population of 185 million (49% female
and 51% male) with a recorded HIV prevalence rate of 3.1% (PEPFAR, 2016). The 2012
National HIV/AIDS and Reproductive Health Survey (NARHS), which was a more
comprehensive survey compare to the ante-natal clinic (ANC) sentinel survey, reported
the prevalence of HIV at 3.4% (National Agency for the Control of AIDS (NACA),
2015).
There are six geo-political zones in Nigeria: South South, South East, South West,
North East, North West, and North Central (The Federal Republic of Nigeria, 1999). The
distribution of HIV prevalence in Nigeria is not homogenous among the six geo-political
zones. Initially, the southern axes had a comparatively higher rate; but over the years, the
Middle Belt region of the country, made up of parts of North East, and North Central, has
taken over (Bashorun et al., 2014). In 2012, South South, had the highest prevalence of
5.5%, while South East had the lowest prevalence of 1.8%.
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Figure 1. HIV prevalence by geopolitical axes including national rates.
Compared to the national prevalence of 3.0% in 2012, only South West and South
East (with prevalence of 2.8% and 1.8%, respectively) had less than the national
prevalence as displayed in Figure 1 (National Agency for the Control of AIDS (NACA),
2015). In 2012, four states shown in Figure 2 had a prevalence greater than 8%, including
Rivers (15.2%), Taraba (10.5%), Kaduna (9.2%), and Nasarawa (8.1%) respectively
(National Agency for the Control of AIDS (NACA), 2015).
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Figure 2. Spread of HIV prevalence by states (National Agency for the Control of AIDS
(NACA), 2015)
There is a disparity in prevalence between urban and rural settlement with the
former having a higher prevalence of HIV (Mahy et al., 2014). Also, the prevalence was
higher among female than male with 4.0% and 3.2% respectively in 2007. Five years
later (2012), the female rate declined to 3.5% but was still higher than the male rate of
3.3% (National Agency for the Control of AIDS (NACA), 2015). The age group 35 – 39
years had the highest prevalence in 2012 with 4.4% compared to age 15 – 24 which
accounts for 42% of new infections globally (Kharsany & Karim, 2016; Wang et al.,
2016).
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The incidence of HIV peaked in 2009 with 278,061 new infections, and the rate of
new infections has continued to decline with 262,238 in 2011, 239,155 in 2013 and 227,
518 in 2014 (National Agency for the Control of AIDS (NACA), 2015). Table 1 shows
the trend of HIV incidence in Nigeria between 2009 and 2014. In 2015, Nigeria was
responsible for over 30% of new infection among children globally (President's
Emergency Plan for AIDS Relief [PEPFAR], 2016).
Table 1
Showing Trend of New Infection
Year

Female

Male

Total

2009

151,495

126,566

278,061

2010

145,245

123,422

268,667

2011

142,542

119,696

262,238

2012

137,671

115,835

253,506

2013

129,976

109,179

239,155

2014

123,601

103,917

227,518

Source: National Agency for the Control of AIDS, 2015.
Mortality
The total number of deaths from HIV in Nigeria is unknown because there was no
proper data documentation at the initial stage of HIV outbreak in the country. However,
available data showed that mortality rate dropped from over 210,0000 in 2013 to slightly
above 174, 000 in 2014 (President's Emergency Plan for AIDS Relief [PEPFAR], 2016).
The figure from the agency officially mandated by the federal government of Nigeria to
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control HIV in the country, the NACA, estimated that 180,000 deaths in 2015 resulted
from HIV-related causes (National Agency for the Control of AIDS (NACA), 2015).
However, on the African continent to which Nigeria belongs, an estimated 790,000
people died of HIV-related causes in 2014, and this was less than the 1.2 million in 2009
and 1.5 million in 2004 (Granich et al., 2015). Maternal death related to HIV is fast
emerging as the leading cause of pregnancy-related mortality (Onakewhor et al., 2011).
HIV is one of the five preventable diseases that account for more than 70% of the leading
causes of 1 million annual deaths of children under 5 in the world, annually. The other
diseases are malaria, diarrhea, measles, and pneumonia (NACA, 2015). The number of
children orphaned by HIV was estimated to be 1.7 million in 2013 (PEPFAR, 2016).
HIV Mode of Transmission
HIV transmission routes vary widely in different regions of the world. In Eastern
Europe, South America, and Central Asia, the predominant routes are sex, drug, and men
having sex with men (Shaw & Hunter, 2012). In Nigeria, researchers have conducted
many studies on the transmission of HIV in Nigeria over the last two decades. The
converging point for researchers on this seems that the primary means of HIV
transmission in Nigeria remains men who have sex with men (MSM), use of intravenous
drug, sexual contact with commercial sex workers (The Joint United Nations Programme
on HIV and AIDS UNAIDS, 2010). Others means include through, blood transfusion,
blood products, and maternal-infant infection (Shubber, Mishra, Vesga, & Boily, 2014;
UNAIDS, 2010). Among the most at-risk populations, there has been a shift in
prevalence. The group includes female sex workers, men who have sex with men (MSM),
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long journey travelers, and IDUs (NACA, 2015). There is a prevalence of 27.4% among
brothel-based female sex workers, 21.7% among non-brothel-based female sex workers,
and 17.2% for MSM (National Agency for the Control of AIDS (NACA), 2015). Two
decades ago, sex workers were thought to have the highest prevalence of HIV, but that is
fast changing as the prevalence for MSM was 13.5% in 2007, but rose to 23% in 2015
(Entonu & Agwale, 2007).
Intervention and Adherence Challenges
International health initiatives have focused on expanding access to ART in
countries with high levels of HIV endemicity, including Nigeria ART (Monjok, Smesny,
Okokon, Mgbere, & Essien, 2010). The incidence of HIV in Nigeria peaked in 2009 with
278,061 new infections, and the rate of new infections has continued to decline with
262,238 in 2011, 239,155 in 2013, and 227, 518 in 2014 (National Agency for the
Control of AIDS (NACA), 2015). The estimated total number of deaths due to HIV in
Nigeria is unknown because there was no proper data documentation at the initial stage of
HIV pandemic in the country. However, available data showed that the mortality rate
dropped from over 210,0000 in 2013, to slightly above 174, 000 in 2014 (PEPFAR,
2016). The figure from the agency officially mandated by the Federal Government of
Nigeria to control HIV in the country, NACA estimated that 180,000 deaths in 2015
were due to HIV-related causes (NACA, 2015).
About two decades ago, the available ARV medicines were beyond the reach of
most who were in need in Nigeria because the cost for a year treatment was between
$5,000 - $15,000 (Bendavid, Leroux, Bhattacharya, Smith, & Miller, 2010). The Doha
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Declaration on the Agreement on Trade-Related Aspects of Intellectual Property Rights
by the World Trade Organization in 2001 (Hoen, Berger, Calmy, & Moon, 2011) was a
milestone that improved access to the ARVs. Before this time, ARVs were patented,
thereby making it difficult for low - and medium-income countries to have access to it
(Hoen et al., 2011). Unlike the ugly situation where only one in 1000 had access to ARVs
in Africa in the late 1990s, there are several treatment centers now in sub-Saharan Africa
(Kharsany & Karim, 2016). The increased access to ART has led to the decline in the
number of new infections (Pustil, 2016). Sub-Saharan Africa, which constitutes only 12%
of the world population, is still home to between 66% and 71% of HIV prevalence
globally (Kharsany & Karim, 2016). While HIV incidence in Nigeria, when compared to
other African nations, has been steadily low, its global share is huge because of its size
with an estimated population of 180 million people (National Population Commission, n.
d.).
With the intervention of the United States government through the PEPFAR in
2001, ARVs became free for those enrolled in care in treatment centers in Nigeria
(Collins & Beyrer, 2013). However, that also came with adherence challenges because
ARVs are drugs to be taken for life. No matter the potency of the ARVs, without
adherence to prescribed regimen ARV, there will be no effective management of HIV. In
Nigeria, as in advanced nations, adherence to antiretroviral therapy (ART) has its
challenges. According to Monjok et al. (2010) who did a systematic review of 13
published studies on adherence in Nigeria, the success of the ART expansion programs
by global health initiatives is depended on individuals’ adherence to HIV medicines.
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Adherence is associated with most of the parameters that defined a good ART outcome
such as low viral load, high CD4 counts, and low morbidity and mortality.
Adherence has virologic, immunological, and clinical implications for HIV
management outcomes. For example, poor adherence in pregnancy is known to increase
disease progression and increase the risk of virus transmission to the child (Bailey et al.,
2014; Ekama et al., 2012; Kanters et al., 2016; Nachega et al., 2016; Vitalis, 2013).
Studies among geriatric patients also have shown that adherence is a challenge that cut
across all ages (Jin, Kim, & Rhie, 2016). In a comprehensive systematic review and
meta-analysis study of adherence in adolescents and young adult aged 15–24 years from
53 countries, 62.3% was found to be adherent. The highest adherence rates were from
Africa (84%) and Asia (84%). This was followed by South America (63%), Europe
(62%), and North America (53% ) had the poorest rates of adherence (S.-H. Kim, Gerver,
Fidler, & Ward, 2014). A meta-analysis of adherence in sub-Saharan Africa indicated
adherence rates of less than 80% among 23% of Africans (Croome, Ahluwalia, Hughes,
& Abas, 2017). While there is no particular cut-off mark for adherence to be described as
good adherence, most studies framed an adherence rate of 85% and above as good
adherence (Falang, Akubaka, & Jimam, 2012; Suleiman & Momo, 2016a). Adherence
rates among people living with HIV (PLHIV) in Nigeria vary considerably depending on
the instrument used in the measurement. There are several ways to measure adherence
which include direct measures, secondary database analysis, electronic medication
packing, pill count, clinician assessment and self-report (Lam & Fresco, 2015). Patient
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self-report, pharmacy refill records and pill counts are the commonest instruments of
measure (McMahon et al., 2011).
In a descriptive cross-sectional study of participants accessing ART care in a
tertiary institution in a southern Nigeria urban setting, 411 people living with HIV were
interviewed about their adherence to ARVs in the week before the study. Researchers
found the total adherence rate to be 59.9%. (Oku, Owoaje, Ige, & Oyo-ita, 2013; Oku,
Owoaje, Oku, & Monjok, 2014). A related study in a rural setting in the same sub-region
in Nigeria showed a 50.4% adherence rate (Oku et al., 2014). Onyeonoro et al. (2013)
found a good adherence rate in the southern sub-region of Nigeria in the study of
adherence among 282 children ages 4 months to 15 years in Nnamdi Azikiwe University
Teaching Hospital, Nigeria. Adherence rates were 92% for females, and 90% for males.
In a study in Ilorin, South-West Nigeria sub-region, Bello (2011) found that adherence
rates meased through pill count and self-report for a 20-month period in May 2009–
December 2010 was 73.3%. A study in the Middle - Belt region of Nigeria reported a
better adherence. In a cross-sectional study of 250 participants who had been enrolled in
care at the Federal Medical Center Keffi for more than 6 months, researchers found that
62.8% had more than 95% adherence rate, while 31.2% reported 100% adherence rate
(Pennap, Abdullahi, & Bako, 2013). Adherence inhibitors have been found to include
stigma associated with taking ARVs, the cost of ARVs (suffice to say the drugs are
heavily subsidized), side effects associated with ARVs, and education level (Ankrah et
al., 2016; Gare et al., 2015). According to Ankrah et al. (2016), other factors include
distance from the clinic as reported by patients, transportation costs, and forgetfulness. In
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addition, marital status, occupation, health-related illness polypharmacy, and
unavailability of ARVs are said to impact adherence (Ankrah et al., 2016; Gare et al.,
2015; Jin et al., 2016; Shigdel, Klouman, Bhandari, & Ahmed, 2014).
Problem Statement
Adherence is a term used to describe the extent to which a patient's behavior
relating to medical treatment aligns with what was collectively agreed to between the
patient and prescriber (Bello, 2011). Poor adherence to ART has been associated with
failure of therapy, whereas good adherence is essential for the desired treatment
outcomes such as improved quality of life and survival (Akahara, Nwolisa, Odinaka, &
Okolo, 2017). For most of the countries where HIV is endemic like Nigeria, refill of
ARVARVs at treatment centers is based on appointment (Mori & Owenya, 2014).
Patients are thus expected to also adhere to their clinic dates soas to have their
prescriptions refilled. The ARV medicines are free of charge in Nigeria and other subSaharan Africa with support from the U.S. government and other foreign agencies
(OGAC, 2014). The problem, however, is that HIV patients rarely attained a 100% rate in
their pharmacy ARV refill. Pharmacy ARV refill is a proxy measure of adherence to
ART (Sangeda et al., 2014a, 2014b). There have been reported challenges that inhibit
adherence as enumerated earlier on such as transportation cost, forgetfulness, side effects
associated with the ARVs and stigma (Arnet, Walter, & Hersberger, 2013; Groh et al.,
2011; Hatah, Lim, Ali, Mohamed Shah, & Islahudin, 2015). The life-saving significance
of the ARV medicines notwithstanding, adherence has been a challenge among AYA
(Ankrah et al., 2016).
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Globally, while 83% of adolescents living with HIV are in sub-Saharan Africa,
their ART outcomes are poor when compared to adults (Ankrah et al., 2016; Maskew et
al., 2016). Also, once on ARV, one is expected to be adherent to obtain and maintain
good health outcomes (Heestermans, Browne, Aitken, Vervoort, & Klipstein-Grobusch,
2016). However, poor adherence has been reported among people with prior good
adherence (Ngarina, Popenoe, Kilewo, Biberfeld, & Ekstrom, 2013). Some of the
inhibitors to adherence among this population include financial barriers, adverse side
effects of the ARV, forgetfulness, and stigma (Gare et al., 2015; Shigdel et al., 2014).
Thus far, there have been no studies in developing nations comparing rural and urban
settings’ impact on adherence. A study in Uganda indicated that rural health facilities
were associated with poor adherence measured by hospital prescription refill for patients
who reside and access care in such rural areas (Nabukeera-Barungi et al., 2015). There is
therefore a need to explore such association for patients who live in the rural area but
access their care in faraway urban settings. Also, distance to the treatment center as
reported by patients has been cited as an inhibitor of adherence (Conley et al., 2012).
However, no known study has explored this further using patient hospital records to
correlate such claims.
Purpose of the Study
The purpose of the research was to explore the difference in adherence rate to
ART in patients who resided in a rural setting and those who resided in urban settings.
Because patients have reported distance as a barrier, I also stratified the population by
distance to the treatment center and explored for correlation with adherence. In addition, I
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explored relationship between a high CD4 count and adherence. Therefore, the specific
goals of the quantitative study were (a) to explore the difference in adherence among
adolescents and young adults (AYA) accessing care in the same treatment center but
resident in rural and urban settings, (b) to explore the association between adherence in
AYA stratified by distance from treatment center, (c) to determine the nature of the
relationship between adherence and CD4 counts after an adolescent or young adult
attained a good CD4 cell count greater than 500 cell/ mm3.
Research Questions
I developed the following three research questions (RQs) for this study:
RQ1: What is the difference in adherence to ART among AYA accessing ARV
medicines in the same treatment center but residing in rural and urban settings?
Ho1: There is no statistically significant difference in adherence to ART among
AYA accessing ARV medicines in the same treatment center but residing in rural and
urban settings
Ha1: There is statistically significant difference in adherence to ART among
AYA accessing ARV medicines in the same treatment center but residing in rural and
urban settings
RQ2: What is the association between distance from treatment center and
adherence to ART among AYA?
Ho2: There is no statistically significant association between distance from
treatment center and adherence to ART among AYA
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Ha2: There is statistically significant association between distance from treatment
center and adherence to ART among AYA.
RQ3: What is the relationship between a high CD4 counts (> 500 cell/mm3) and
adherence to ART among AYA?
Ho3: There is no statistically significant relationship between a high CD4 counts
(> 500 cell/mm3) and adherence to ART among AYA.
Ha3: There is statistically significant relationship between a high CD4 counts (>
500 cell/mm3) and adherence to ART among AYA.
Theoretical Framework
The theoretical base for the study was the transtheoretical model (TTM) of
behavior change. The theory holds that health behavior change involves six stages, which
include pre-contemplation, contemplation, preparation, action, maintenance, and
termination (Prochaska & Velicer, 1997). The theory was developed by Prochaska and Di
Clemente (2005) in 1977 and has been used widely in the study of patient health behavior
change programs like physical exercise, adherence, diet, and smoking cessation (van
Leer, Hapner, & Connor, 2008a). Recently, the theory has gained popularity in
understanding patients’ adherence to medicines (Johnson et al., 2006). TTM served as my
framework for understanding changes in adherence as AYA living with HIV continue to
take ARV medicines. In Chapter 2, I offer a detailed explanation of the theory.
Nature of the Study
This was a quantitative study with a cross-sectional design (see Creswell, 2009;
Gordis, 2009). When making a choice of research design, it is important to ensure that the
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design is appropriate for the study and would lead to a valid conclusion (Creswell, 2009).
Researchers use cross-sectional studies to describe a pattern of relationship between
variables (Mann, 2003). Also, cross-sectional studes are efficient, effective, easy and
quick to conduct, and can easily be reproduced (Campbell & Stanley, 1963; C FrankfortNachmias & Nachmias, 2015). Therefore, the design was appropriate for my study in
which I sought to explore the relationship among the various variables that impact ART
adherence. Independent variables in the study included CD4 cell counts, the distance
between patient's home and treatment center, and the type of the home environment
(urban or rural). The dependent variable was adherence. I will thoroughly discuss the
study methodology in Chapter 3.
Definitions of Study Variables and other Terms
Acquired immune deficiency syndrome (AIDS): A collection of symptoms that is
best described as a syndrome caused by HIV (Sharp & Hahn, 2011).
Adherence: A term used in describing the extent to which a patient's behavior
relating to medical treatment agrees with what was collectively agreed with the prescriber
(Bello S.I, 2011).
Adolescent: A person between 10 and 18 years old. Defining adolescent strictly
from the perspective of age has been criticized by many. A complete definition of an
adolescent should consider the biopsychosocial stage of a young person entering an adult
stage of life (Curtis, 2015).
CD4 count: A test that measures the number of CD4 cells in the body. These CD4
cells, also called T cells, are the type of white cells that defend the body against infection.
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It does not measure HIV but is a surrogate HIV marker that indicates not just presence of
HIV but how much damage it has caused to the body. CD4 count serves as an indicator of
body immunity (Nwokedi, Ochicha, Mohammed, & Saddiq, 2007).
Distance to treatment center: This refers to the distance between the ART center
and where the participant resides.
Geopolitical zone: Refers to the zones in Nigeria based on geographical location
and political consideration. Economic, political, and educational resources often are
shared across the zones (Ibrahim & Ibrahim, 2014).
HIV treatment center: This is a designated health facility for management of
HIV/AIDS.
Human immunodeficiency virus (HIV): The virus that spreads through bodily
fluids and causes AIDS, a life-threatening disease, by attacking CD4 cells.
Mortality: Incidence of death with a particular group in a specified period.
Pharmacy refill: Prescription refill in pharmacy.
Rural: This refers to a hamlet or village settlement.
Self-disclosure: The act of revealing information about oneself to another person
(Nöstlinger, Bakeera-Kitaka, Buyze, Loos, & Buvé, 2015).
Self-report: Report about a patient as presented by the patient.
Serodiscordance: A term use in reference to a couple that has “mixed serostatus.”
That is one partner is HIV-positive while the other is HIV-negative (Irungu et al., 2016).
Urban: This refers to a town or city settlement.
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Young adult: According to WHO, a young adult is a person aged 12–24 (Geiger
& Castellino, 2011).
Justification for Set Values
CD4 counts. The research question four (RQ4) set CD4 counts at 500 cells/mm3
to assess adherence because the standard CD4 counts for a healthy person is between
500 cells/mm3–1500 cells/mm3 (Ying, Granich, Gupta, & Williams, 2016). Normally,
those with CD4 below 500 cells/mm3 are unlikely to feel well compare to those with
CD4 above 500 cells/mm3 (Crampin, Mwaungulu, Ambrose, Longwe, & French,
2011).
Distance to treatment center: The distance between client’s resident and the ART
center.
Assumptions
I made the following assumption when conducting this study:
•

I would have unrestricted access to the medical records of clients accessing
HIV care at FMC Makurdi located in Benue State, Nigeria to extract the
requisite data for the analysis.

•

There would be maximum cooperation from the staff of the medical record
department in the FMC Makurdi in the process of data abstraction from
patients’ medical records.

•

Physicians, nurses, pharmacists and all the health care workers in the FMC
Makurdi collected and documented accurate primary data of clients such that
conclusions based on the data will reflect the truth.
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•

My analysis based on data obtained from AYAs from FMC Makurdi that has
over 10,000 patients would be a true representation of AYA in Benue State,
Nigeria.

•

My research assistants would be very honest in data extraction and as such
information extracted from the clients’ medical records would be accurate and
valid.
Scope and Delimitations

I explored the adherence rates of AYAs in Nigeria accessing ART between 2011
and 2014 to see how the group differs with respect to distance, CD4 counts and type of
environemnt. Adherence is crucial for the successful management of HIV globally. AYA
are the links between pediatric and adult, and as such, poor adherence to ARVs from this
group could mean a serious public health issue given that one has to remain on these
drugs for life. HIV is prone to becoming resistant to ARVs if the adherence component of
HIV management is not handled carefully. Once there is resistance to any ARV, HIV
infection becomes a public health challenge.
The study was restricted to data from AYA who are living with HIV/AIDS and
are currently enrolled in ART in the FMC Makurdi, Benue State, Nigeria. I used a
retrospective, correlational, cross-sectional design for quantitative analysis (Gordis,
2009). This methodology is employed when a researcher wants to explore relationships
between variables without establishing causation (Campbell & Stanley, 1963; C
Frankfort-Nachmias & Nachmias, 2015; Mann, 2003). This study does not establish
causality but shows association, so the methodology is appropriate because the focus of
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my research was not to establish causality but to explore the nature of relationship
between adherence rate and predictor variables—namely CD4 counts, distance from ART
center and nature of settlement among adolescents and AYA. Also, the secondary data I
used was collected at one particular point in time, which fulfills the requirements of a
cross-sectional study. Another merit of the cross-sectional methodology is that it could be
used for description of the odds ratio, absolute risks, and relative risk from prevalence
(Thompson, Myers, & Kriebel, 1998).
Limitations
•

Adherence has relationship with other variables that have been studied, but
my research was limited to the relationship between adherence and CD4
counts, distance from a treatment center, and residential setting (urban/rural).

•

There could have been other factors that confound the correlation between
adherence and the variables in the study that influenced the outcome variable.

•

Findings from the study might not apply to all environments in the world as
several factors influence adherence including economy, culture, and political
environment. Also, one of the disadvantages of a cross-sectional study is
limited generalizability of the study because it is a snapshot study that is not
always a representative (Sedgwick, 2014).

•

Part of the data on adherence was based on patient self-report. Self-report has
a validity problem resultant from respondents’ desire to appear “acceptable”
(Jimmy & Jose, 2011; Lam & Fresco, 2015). For example, a young HIV
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positive unmarried woman could lie that she is married in order not to be seen
as social deviant in some communities.
Significance
ART adherence improves quality of life, reduces hospitalization with attendant
cost implications, and reduces the incidence of HIV-related morbidity and mortality
(Falang et al., 2012). Adherence at rates below 85% a serious public health issue because
it potentially causes resistance to the currently limited available ARVregimens
(Kadhiravan, 2013). For example, resistance to first-line ARVs means a patient would
have only a second-line regimen and salvage regimen as the remaining options (Masikini
& Mpondo, 2015). There is an attendant increased total health cost associated with poor
adherence as well because health outcome is impacted negatively, thereby increasing the
frequency of clinic visits, transportation costs, and pill burden with an additional cost
implication. Non-adherence has been linked to treatment failure as well (Inzaule, Hamers,
Kityo, Rinke De Wit, & Roura, 2016).
Two-thirds of new infections of HIV in 2012 were among AYA aged 15-24 years
(Bekker, & Hosek, 2015). Between 2002 and 2012, AIDS-related mortality dropped by
30% for all age categories except AYA, whose rate increased by 50% for the same period
(Bekker et al., 2015). The research is unique because despite many studies on factors that
negatively influence adherence among AYA, researchers have not explored the effect of
an environment such as urban or rural setting. Also, if the distance to a treatment center is
stratified and there is no correlation with adherence, then findings from the research
would shed knowledge on a need for a shift in the current adherence strategies.
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Furthermore, identifying an adherence inhibitor would call for a counter strategy that
would be in line with the ambitious treatment target of the UNAIDS to have viral
suppression in 90% of people living with HIV globally (UNAIDS, 2014). For a HIV-free
generation, viral suppression in 90% of the infected population is essential.
Implication for Social Change
The positive social change implications of the study cannot be overemphasized.
Given the high prevalence of AYA under care in ART in Nigeria (John, Okolo, & Isichei,
2014), my findings may help in several ways. The findings may identify potential factors
that influence adherence to ARV medicines among AYA. Adolescence is an important
stage in life because it is the transitionary stage from childhood to adulthood. This comes
with attendant challenges including psychological problems, sexual health issues,
aggression and violence, health problems, and physical and emotional changes (Shlafer et
al., 2014). Thus, findings could provide a scientific basis for a shift in the current
adherence strategies in the management of HIV patients. Further, they could form the
basis for health policy makers to develop measures that will place emphasis on adherence
among AYA. Poorly managed adherence to ARV is a potential for development of drugresistance, which could become a public health issue that will impact treatment and
management of HIV in the country because there are limited ARV options available
(Cihlar & Fordyce, 2016)
Findings could also help to provide insight for health care providers into
correlates of adherence to ARV medicines by AYA. A strong correlation between
distance to treatment center and residential address of clients could be a call for a robust
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adherence counselling during enrolment in HIV care, with emphasis on encouraging
clients to choose treatment centers that are proximal to their locations. This may, for
example, lead to increasing the number of health facilities providing ART so as to
encourage those living with HIV and ready to enroll in care to do so in health facilities
closer to their localities. The research findings could also have potential for patients
themselves by encouraging them to appreciate the role of adherence even when CD4
counts are high. Overall, a good adherence has potentials for decreased disease
progression, improved quality of life, decrease rate of hospital visitation, reduced cost,
and reduced burden on health systems. As a result, there may be more money available
for other development projects benefitting all Nigerians.
Summary
Medication adherence is important in the management of HIV/AIDS. Poor
adherence has the potential to become a public health issue because adherence is
associated with virologic, immunologic, and clinical outcomes. While 80% of HIVinfected persons in sub-Saharan Africa are adolescents, their rate of ART adherence is
poor compared to other populations.
In Chapter 1, I provided background on HIV in Nigeria and globally. The virus
disproportionally affects AYA in sub-Saharan Africa. I also discussed the prevalence of
HIV by zones in Nigeria. The problem statement was introduced, which highlighted the
existing gap in the literature on adherence to ART among AYA. I then introduced the
three research questions, with adherence as the outcome variable while the distance to the
treatment center, CD4 counts, and type of residential setting (urban/rural) were the the
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predictor outcomes. I also introduced the theoretical framework upon which I built the
study, and discussed the study’s purpose and significance. In the next chapter, I review
the current literature on ART adherence among AYA.
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Chapter 2: Literature Review
Introduction
I conducted a literature review to develop a comprehensive understanding of the
current scientific knowledge on adherence in ART among AYA adults with a focus on
Nigeria. Adherence is an essential component of HIV/AIDS management that, when
compromised, affects the desired therapeutic effect of ART (Castro, Gonzalez, & Perez,
2015).This review will encompass all the variables in my research work, which included
CD4 cell counts in relation to location of ART treatment centers and rate of adherence.
Also, the influence of environment (urban or rural dwelling) on adherence by people
living with HIV will be reviewed. Further, I review factors that influence adherence
together with measurement of adherence. ART adherence and public health are reviewed
as well.
The theoretical base for the study was the TTM of health behavior change. It is
also called the stages of change model, and it holds that health behavior change involves
six stages which include pre-contemplation, contemplation, preparation, action,
maintenance, and termination (Prochaska & Velicer, 1997). The theory has been used
widely in the study of patient health behavior change programs involving physical
exercise, adherence, diet, and smoking cessation (van Leer et al., 2008a). In recent time,
the theory has gained popularity in understanding adherence to medicines (Johnson et al.,
2006). TTM served as the framework I used to understand changes in adherence as AYA
living with HIV continue to take ART. The chapter will end with a highlight of findings
from the literature review and the summary of the chapter.
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Literature Search Strategy
I used a variety of electronic bibliographic databases to carry out the literature
search, including PschINFO, MEDLINE through PubMed, ProQuest, Science Direct,
Google Scholar, and Cumulative Index to Nursing and Allied Health Literature
(CINAHL). The search was focused mainly on articles written in English and published
from 2011 to present. Key search terms included Nigeria, HIV, antiretroviral, CD4
count, urban, rural, adolescents, young adults, distance, adherence, adherence
inhibitors, adherence facilitators, youth, children, ART, pharmacy, pharmacy refill, and
resistance. I used Boolean operators terms such as AND, OR, and NOT to combine the
various key search terms. I considered only articles and books with specific relevance to
the dissertation focus.
Theoretical Framework
People in care receiving ART are expected to adhere to their treatment to achieve
a good health outcome. Remaining adherent is important because patients may need to
protect an unborn child or uninfected partner, and typically desire to get better and
remain healthy (WHO, 2015). While adherence is desirable, for some people, attaining
and maintaining adherence of greater than 85% is hard. In this section, I will discuss
three theories that I used or considered using for my research.
The health belief model (HBM) was first developed by Hochbaum, Rosenstock
and Kegels in the 1950s. The model explains health behavior and researchers use it to
predict individuals’ health behaviors (H.-S. Kim, Ahn, & No, 2012). The model has six
constructs that predict health behavior, including risk susceptibility, risk severity, benefits
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to action, barriers to action, self-efficacy, and cues to action (Jones et al., 2016). In the
HMB, if an individual perceives the benefit of an action to be greater than the perceived
threat or risk of not acting, then the individual will act (Kim et al., 2012). While the HBM
is important, I did not use it because of the inherent weakness of the HBM which include
non-inclusion of positive effects of negative behaviours and social influence (Jones et al.,
2016; Munro, Lewin, Swart, & Volmink, 2007). Another theory widely used in health
behavior is social cognitive theory (SCT), which began as social learning theory (SLT)
by Albert Bandura in the 1960s. The theory posits that learning occurs in a context that
result from interaction of environment, the person, and behavior (Stacey, James,
Chapman, Courneya, & Lubans, 2015; Tougas et al., 2015). The model could also be
used as a framework to explore adherence to ART among AYA. However, I did not use it
because its wide-ranging focus makes it difficult to operationalize the theory (Munro et
al., 2007). I therefore, used the TTM discussed below for my study.
The TTM of health behavior change, also called the SCM, is a model developed
by Prochaska and Di Clemente in 1977 (Prochaska & DiClemente, 2005). They named
the model “transtheoretical” because it incorporated elements from different
psychotherapy theories. Researchers use it widely in the study of health behavior. The
theory holds that health behavior change involves six stages, which include precontemplation, contemplation, preparation, action, maintenance, and termination
(Prochaska & Velicer, 1997). These stages serve as lenses for understanding adherence to
ARV among AYA. Among SCT, TTM and HBM, the TTM fit best into my study, as I
show in the following detailed explanation of the theoretical framework.
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The Transtheoretical Model
The popularity of the TTM in research involving health behavior is
understandable because the theory is useful for categorizing health behavior into
constructs that explain why individuals tend to take some action regarding their health
(Prochaska & Velicer, 1997). The focus is the patient’s readiness to change. The theory
has been used widely in the study of patient health behavior change programs such as
those for physical exercise, diet, and smoking cessation (van Leer et al., 2008a).
Recently, the theory has gained popularity in understanding adherence to medicines
(Johnson et al., 2006). It may be of help for health care providers in predicting adherence
of their clients to ART (Genberg, Lee, Rogers, Willey, & Wilson, 2013).
Precontemplation. Precontemplation is the stage where behavioral change is not
taken seriously by individuals (van Leer et al., 2008a). It is the stage of diagnosis of
illness or commencement of medication where the individual concerned needs to take
ownership of the issue at hand by understanding consequences of action and inaction—
for example, the negative or positive consequence of not taking or taking prescribed
medicines (Konkle-Parker, 2001). In this stage, individuals can be grouped into two
categories: those who are ignorant that it is possible to change their behavior. and those
who deliberately decide there is no need to change behavior (van Leer et al., 2008a). The
individual in this stage typically is not contemplating making any decision in the next 6
months (Genberg et al., 2013). The advent of ARV on a public health scale in subSaharan Africa initially was a concern amongst health officials because poor adherence
holds potential for viral resistance. However, years after, adherence to ART in
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developing nations has been found to be equal, or in some circumstances better, than that
in the Western world (Chung et al., 2011). For the ART-naïve patient at the stage of
precontemplation, researchers have found that adherence counselling is effective in
improving adherence. In a randomized controlled trial study at the Coptic Hope Center
for Infectious Diseases in Nairobi, Kenya conducted between May 2006 and September
2008, adherence of 310 participants was compared between those who had intense
adherence counselling at the ART initiation stage and those who did not (Chung et al.,
2011). According to Chung et al. (2011), participants who got adherence counselling at
the initial stage were comparatively better in remaining adherent. That is, they were 29%
less likely to have monthly adherence of less than 80% There were also 59%
comparatively less likely to experience viral failure (HIV-1 RNA ≥ 5,000 copies/ml)
compared to those who received no counseling (Chung et al., 2011).
Contemplation. Contemplation is the stage where an individual considers
changing behavior, taking into consideration benefits and risks involved in the change.
The contemplative individual could be likened to someone on the fence considering
jumping to either side of the divide. At this stage, there is acknowledgement of existence
of problem, but no certainty on whether to act or not. Therefore, individual is considering
making a decision in the next 6 months, and as such, could be said to be in a state of
ambivalence (Genberg et al., 2013). In a randomized controlled trial in New England for
137 participants accessing ART, adherence to ARV at an early stage (contemplation and
pre-contemplation stages) was compare with that at a later stage (maintenance state). The
mean age for the 22% female, 48% white, and 28% African American population was 42
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years (Genberg et al., 2013). According to the study, those in the early stage had
adherence that was significantly lower (-9.8%, p = 0.04) compare to those in maintenance
stage.
Preparation. At this stage the individual becomes more serious regarding the
need for action towards change and is comparatively less ambivalent (van Leer, Hapner,
& Connor, 2008b). This is the stage where you hear statements like “there is every need
for me to do this now,” “I think I can do it,” and “what do I do?” People in this stage try
to get information and resources that would help them change their behavior, and at this
stage, self-efficacy plays an important role in transiting to the action stage (Jeon, Kim, &
Heo, 2014). Too often, some skip this stage to the next phase called “action” (Jeon et al.,
2014).
Action. Action is the stage where individuals are actively engaged in modifying
their behavior (Prochaska & Velicer, 1997). There is the confidence to make a change
and the amount of time spent here differs, as it could literally be within an hour and could
also take months (generally found to be within 6 months). Individuals in this stage are
open to receiving help and may also seek help from others. To the changer, it is the time
when new skills, both cognitive and behavior are learned and applied for a change
(Konkle-Parker, 2001).
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Stage
Standard
time

Precontemplation
More than six
months

Contemplation
In the next six
months

Preparation
In the next
month

Action
Now

Maintenance
At least six
months

Termination
Anytime

Figure 3. Modified diagrammatical representation of TTM and time.
Maintenance. This is a stage where the new health behavior is incorporated into
an individual’s way of life. Individual here make efforts to sustain the new behavior by
constantly reminding themselves of the change they have made. In ARV adherence, this
is a very important stage. The goal of this maintenance stage is to sustain the newly
learned behavior and resist every temptation to return to the old behavior by devolving
strategies that overcome lapses becoming complete of reversal (Chung et al., 2011;
Genberg et al., 2013; Konkle-Parker, 2001).
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Termination. Termination is where there no desire to return to the old way of
doing things (Johnson et al., 2006). According to Prochaska and DiClemente, (2005) and
Prochaska and Velicer, (1997) at this stage former behavior are no more desirable. From
the model in figure 1, these stages are cyclical implying one could exit and re-enter at any
stage.
Global Overview of HIV
Since the discovery of the first case of HIV in 1981, the number of people
infected with the virus has continued to rise (Sharp & Hahn, 2011). In some countries,
while the incidence has declined, prevalence has continued to increase partly due to
increase in lifespan of those on ART (Wang et al., 2016). According to Wang et al.,
(2016), the peak of HIV incidence globally was in 1997 with a size of 3.3 million people,
and this continued to decrease at the rate of 4.8% per year until the year 2005. Between
2005 and 2015, the incidence remained steady at about 2.5 million infections per year
(Wang et al., 2016). Among adult females living with HIV in 2015, 17.8 million
representing 51% was those that were 15 years and older whereas adolescent girls
constituted 60% of young people living with HIV and this represents 2.3 million human
beings (UNAIDS, 2016). In 2015, among the 1.8 million adults with new infections, 47%
were female, and 58% of the new infections were in the age category of 15 -24 years. At
a global level, there were differences in new infections and proportion of prevalence
among young adult male and female between age 15 and 24 years (WHO, 2015). In 2015
for instance, in eastern Europe and central Asia, 31% of the new infection among
females, 46% was between age bracket of 15 and 24. For the same period, in North
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Africa and the Middle East, of the 38% of new infections among adult female, 48% was
between aged 15 and 24 years (Wang et al., 2016). In Latin America, there was 29% new
infection that was an adult female and the age bracket 15 – 24 years constituted 41%. As
for Asia-Pacific, new infection among adult female was 32% while age bracket 15 – 24
years was 41% (Wang et al., 2016). There was a difference in new infection in western
and central Europe and North America where 22% new infection was recorded among
adult female with 29% aged between 15 and 24 years (Nations, 2015).
The prevalence of HIV, on the other hand, rose from 2.4 million in 1985 to 28
million in the year 2000 while between 2000 and 2015, the number of people living with
HIV increased by 0.8% per year (Wang et al., 2016). In 2015, the world prevalence of
HIV/AIDS was 38.8 million (Fettig, Swaminathan, Murrill, & Kaplan, 2014; Wang et al.,
2016). Mortality of HIV had its peak in 2005 with 1.8 million deaths, and this dropped by
5.5% per year to 1.2 million in 2015 with the highest mortality rate in sub-Saharan Africa
(Wang et al., 2016). In 2015, 1.8 million children under the age of 15 years were infected
while 100,000 was associated with AIDS-related deaths (Wang et al., 2016). The new
infection was 150, 000 but incidence has dropped by more than 70% since 2001 (Kaiser
Family Foundation, 2016). In 2015, there were 1.8 million new infections of which subSaharan Africa had a disproportionate burden of 75.4%, South Asia 8.5%, Southeast Asia
4.7%, and East Asia 2.3%. HIV rates across countries also vary significantly with the
highest rate in Southern Africa with more than 1% in Lesotho, Botswana, and Swaziland
(Wang et al., 2016). In Europe, Russia has the highest incidence rate while in Asia
Cambodia is the country with the highest incidence (Fettig et al., 2014; Wang et al.,
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2016). Haiti, Guyana, and Belize are the only countries in Americas with a rate greater
than 50 per 100,000 people. Globally, incidence has decreased between 2005 and 2015
while rate has continued in some countries (Wang et al., 2016). The number of people
living with HIV/AIDS who are on ART rose from 6.4% to 38.6% for male while those of
female increased from 3.3% to 42.4% between 2005 and 2015 (Wang et al., 2016).
Overview of Adherence in ART
The term adherence is often used interchangeably with compliance. While both
measure extent to which prescribed medicine is taken by a patient, the latter refers to the
traditional expectation to stick to what a prescriber says while the former has to do with
the extent to which drug is taken as it was agreed by both prescriber and patient (Brown
& Bussell, 2011; Hugtenburg, Timmers, Elders, Vervloet, & van Dijk, 2013). The WHO
defines adherence as a the extent to which person’s drug taking behavior agrees with a
collective understanding the person has with a health care provider (Jimmy et al., 2011).
When medicines are prescribed, it for such to be taken so adherence to medicines is
essential if desired therapeutic response is to be achieved. There is a plethora of studies
on adherence to ARV medicines with different findings on level of adherence and how it
relates to achieving a good therapeutic effect. Adherence has virologic, immunological
and clinical implication on HIV management outcome. For example, poor adherence in
pregnancy is known to increase disease progression and increase risk of virus
transmission to child (Bailey et al., 2014; Ekama et al., 2012; Kanters et al., 2016;
Nachega et al., 2016; Vitalis, 2013).
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Global Overview of Adherence
According to the WHO revised protocol, it is hard to accurately tell who will have
suboptimal adherence using demographics and that individual adherence also varies
(WHO, 2012). In a world-wide systematic review and meta-analysis study of adherence
in adolescents and young adult aged 15 – 24 years from 53 countries, 62.3% was found to
be adherent. The highest adherence was from Africa [84% (95% CI 79–89; I2 : 93%)] and
Asia [84% (95% CI 77–91; I2 : 0%] follow by South America [63% (95% CI 47–77;
I2 : 85%] while Europe [62% (95% CI 51–73; I2 : 97%)] and North America [53% (95% CI
46–59; I2 : 91%)] were the poorest (Kim, Gerver, Fidler, & Ward, 2014). The Kim et al.
(2014) study showed Africa and Asia had the highest adherence suffice to say the
adherence rate was below the generally acceptable level of minimum of 85% (Falang et
al., 2012; Suleiman & Momo, 2016b). Mountain et al. (2014) did a similar world-wide
systematic and meta-analysis study on adherence among female sex workers. Data bases
from Embase and MEDLINE through PubMed, were used where 39 studies relevant to
the review were included. These studies were from Africa, North America, South
America, Central America, Asia and Caribbean. According to the (Mountain et al., 2014),
after enrolment, those lost to follow up was 6% (95% CI: 3%–11%, I2 = 0%, 3 studies)
and those who died after enrollment into ART in was also 6% (95% CI: 3%–11%, I2 =
0%, 3 studies). Those with greater than 95% adherence rate of prescribed pills was 76%
(95% CI: 68%–83%, I2 = 36%, 4 studies), while 57% (95% CI: 46%–68%, I2 = 82%, 4
studies) of FSWs on ART had a viral suppression (Mountain et al., 2014) . From the
study population, 24% were below the desired 95% adherence rate. Factors associated
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with adherence in the studies varied greatly as it was a systematic review that cut across
five continents.
In a related study, Hudelson and Cluver, (2015) carried out a systematic review
and meta-analysis of adherence in low and medium income countries for 4,363
adolescents ages 10 -19 who were on ART. Only quantitative observational studies were
included in the review. Journal and trial databases and conferences databases were used
to search for the published articles that met inclusion criteria. Databases that were used
included MEDLINE (through PUBMED), CINAHL, SIGLE, LILACS, World Health
Organization (WHO), Web of science, Health Library, U.S Institute of Health’s Clinical
Trials Registry. The researchers found adherence varies greatly among nations with
different factors impacting adherence. In the review, adherence was as low as 16% from
Zimbabwean population to as high as 99% among Thai population (Hudelson & Cluver,
2015). In Cuba, a cross-sectional study of 876 patients on ART was carried out for
patients aged greater than 15 years and who have been in care for at least six months
prior to the study. Through administration of questionnaire, adherence rate of participants
was assessed (Aragonés, Sánchez, Campos, & Pérez, 2011). The researchers categorized
adherence into five groups namely perfect adherence (100%), good adherence (95% 99.9%), moderate adherence (80% - 94.9%), poor adherence (1% - 79.9%) and drop out
(<1%). The result showed 62.6% had perfect adherence, 8% had good adherence, 14.1%
had moderate adherence, 13.3% had poor adherence while 2.0% dropped out from care
(Aragonés et al., 2011). From the study, 70.6% (62.6% perfect adherence + 8% good
adherence) of Cuban patients receiving ART had high adherence rate. The relatively
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higher level of adherence recorded in Cuba is consistent with the findings of adherence in
Africa and other developing nations (Hudelson & Cluver, 2015; Kim et al., 2014).
In South Africa, Morojele et al. (2014) studied adherence and correlates such as
alcohol and psychosocial factors. It was a across sectional study where structured
questions were administered on HIV clients accessing care in two district hospitals in
South Africa after obtaining their informed consent. Cohen was used to determine that
304 patients was enough sample size for the study. The study had 205 (68 %) women and
98 (32 %) men in the sample with one participant having a missing gender. About 50% of
the study sample was aged between 30 and 39 years. Because of the likelihood of
differences in some of the determinants under study, both township and a health facility
in city were included. The study looked at the prevalence of HIV in South Africa where
over 1.7 million people are estimated to be living with the virus and carried out an
analysis to see if there was a correlation between the use of alcohol, psychosocial factors
and ART to adherence among ART recipients in South Africa (Morojele et al., 2014).
The aim of the study was to determine association of alcohol with ART non-adherence
over and beyond structural and psychosocial factors. The authors named structural factors
such as food insecurity, transport costs to health facility, travel times to health facilities
and waiting times at clinics. Whereas, HIV stigma and HIV non-disclosure were
considered as psychosocial factors. Multiple regression was used in the analysis because
the study had several predictors with a single dependent variable which is adherence.
Where we have more than two variables, multiple regression becomes a good statistical
test to predict the relationship between those variables (Alexopoulos, 2010). The result
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showed only 54.7% had a good adherence as measured by Center for Adherence Support
Evaluation adherence index with female (59.9%) significantly more likely than males
(43.9%) to report good adherence (v2 = 6.84; df = 1; p\0.01). Also, alcohol plays a role
independent of psychosocial factors in affecting adherence (r = -0.36, p\0.001). Findings
from the study agreed with Achappa et al. (2013) who found a negative correlation
between adherence and alcohol intake. The study by Morojele et al., (2014) is related to
my research because like in my research, adherence is the single dependent variable and
the statistical test used, multiple regression is the same test I intend to use.
Overview of Adherence to ART in Nigeria
Adherence to ART is well a well-studied concept in Nigeria based on the
quantum of publications available compare to other thematic areas of HIV. Adherence to
ART among people living with HIV AIDS (PLWHA) varies across different categories
of patients and location of patients and it is understandable considering the diversity of
Nigeria socio-culturally and economically. Adherence among people living with
HIV/AIDS attending PEPFAR-funded clinic in University of Calabar Teaching Hospital,
Cross – River State in Nigeria was explored using a cross-sectional design (Oku et al.,
2013). Data was collected from 411 eligible participants using semi-structured
questionnaire. The mean age of the participants was 35.7 ± 9.32 years with a higher
number of females (68.6%). Using a logistic regression, the authors found perceived
improved health status [OR 3.11; CI:1.58-6.11], reduced pill load [OR 1.25; 95% CI:
0.46-2.72] and non-use of herbal remedies [OR 1.83; 95% CI: 1.22-2.72] were key
predictors for adherence to ART. Resident outside of Cross River State 42 (72.4%) were
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significantly more likely to be adherent to HAART when compared with 204 (57.8%)
being resident within the state (p < 0.05). This contradict other similar studies that found
distance from treatment center as adherence inhibitor (Arage, Tessema, & Kassa, 2014;
Wasti, Simkhada, Randall, Freeman, & Van Teijlingen, 2012). The study is relevant to
my research from several angles. The demographics of the participants is similar to my
study population. The study design and methodology are similar to my research. While
the study found those within Calabar metropolis had lower adherence compare to those
from a far distance, my research hope to stratify patients distance from treatment center
and explore the association to adherence. Also, my research will objective by using
patient’s medical records to determine distance from treatment center as opposed to selfreport.
In a related study of adherence among pediatrics between less than a year and 15
years, some researchers explored the relationship between duration of treatment, patient
education, and drug administrator and adherence. In a study in Federal Medical Center
Owerri, Imo State Nigeria, 210 participants were enrolled in the study between
September and December 2013 (Akahara et al., 2017). From the 108 males and 102
females, 64 (30.5%) were single orphans, 22 (10.5%) were dual orphans while 146 (9%)
had the drugs administered by their biological parents. The result from the research
showed 191 (91%) with good adherence defined as adherence equal or greater 95%. The
study showed adherence had a significant relationship with patient educational level (𝑝 =
0.004), duration of treatment (𝑝 = 0.001), drug administrator (𝑝 = 0.005), and orphan
status (𝑝 = 0.001). From the study, reason for adherence was patient not feeling as sick as
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before. The study is related to my research work since part of my study is to explore
adherence after a patient on ART start feeling well with increased CD4. My study seeks
to explore association between adherence rate before CD4 count reaches 500 cells/mm3
and after attaining 500 cells/mm3.
The objective of vision ’90-90-90’ by UNAID is to have an HIV-free generation
(UNAIDS, 2016; UNAIDS, 2014) and one way to achieve this is to ensure there is
prevention of mother to child transmission of HIV by pregnant women who are living
with the virus. In a research to explore level of adherence and factors that influence
pregnant women who are on ART, 170 eligible pregnant women accessing care in HIV
Clinic in Nigeria Institute of Medical Research, Lagos were studied (Ekama et al., 2012).
Through a cross-sectional design study, a semi-structured questionnaire was administered
to the participants who were aged 30 – 34 years between September and November 2009.
Using a bivariate and multiple logistic regression, the result showed 137 (80.6%) had
minimum of 95% (≥ 95%) adherence rate. Non-adherent rate was 19.4%. Fear of stigma
(63.6%) was the main reason for non-adherence while the desire to protect the unborn
was the greatest motivation (51.8%). Through a bivariate analysis, factors associated with
good adherence included marital status, disclosure, good knowledge of ART, and having
a treatment support partner (Ekama et al., 2012). The study population comes from a
population that shares similar demographics with my studied population. Also, I intend to
use a cross-sectional design like the study by Ekama et al. (2012). Among adolescent and
young adult in my study population, pregnancy will not be excluded. So, the research by
Ekama et al., (2012) is relevant to my study.
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In a study of patient - factors influencing ART adherence in the Middle-Belt
region of Nigeria, Falang et al. (2012) studied 461 eligible patients accessing care at the
Jos University Teaching Hospital, Nigeria. Interviewer administered structured
questionnaire was used to collect the desired data from eligible participants between
November 2009 and January 2010. In the cross-sectional design study, Falang et al.
(2012) found that adherence was 87.9%. Factors that were found to be strongly
associated with adherence in a univariate analysis included age (OR 1.04), sex (OR 1.14),
employment (OR 1.29), knowledge of ARVs (OR 1.23), pill burden (OR 1.20), HIV
status disclosure (OR 1.08), knowledge of HIV (OR 1.11), thrice daily frequency of drug
intake (OR 1.68), twice daily frequency (OR 2.18), and alcohol non-intake (OR 0.29).
Whereas, in the multivariate analysis, age, frequency of drug intake and alcohol nonintake and twice daily affected adherence (P < 0.05). Findings from the Falang et al.
(2012) study on the strong association between good knowledge of ART and adherence
agrees with the study by Ekama et al. (2012). In a related study, 250 participants
accessing care for ART in Federal Medical Center Keffi, in Nasarawa State Middle-Belt
region of Nigeria were assessed for adherence (Pennap et al., 2013). In the cross sectional
study, Pennap et al. (2013) found adherence rate was 62.8%. Only 78 (31.2%) had
adherence of 100%. Living with family members was strongly associated with adherence
(85.8%) (p ≤ 0.05) and likewise disclosure to a family member 77.6% (p ≤ 0.05). Level
of education and marital status in the study were strongly correlated with adherence in the
study (p ≤ 0.05). The strong association between adherence and disclosure to family
member agreed with Ekama et al. (2012).
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In south west Nigeria, the geo-political zone in Nigeria deemed to be the
relatively most educated, 237 participants who were enrolled into ART care at Sobi
Specialist Hospital were studied (Bello, 2011). The cross-sectional study was between
May 2009 and December 2010 with participants aged 16 – 60 years. Both self-report and
pharmacy re-fill records were used to assess adherence rate among participants.
Pharmacy refills (70.8%) and participant self-report (73.3%) had adherence rate greater
than 95% (≥ 95%). Factors that were associated with adherence included adverse side
effects (6.6%), low education (4.7%), pill burden (3.7%), stigma (3.3%), forgetfulness
(1.4%) (Bello S.I, 2011).
Adherence rates from study by Falang et al. (2012) in Middle-Belt region of
Nigeria who used data of participants in 2009 -2010 was 87.9%. The study by Bello
(2011) who used participants records between 2009 and 2010 from the western region
was 73.3%. In south east Nigeria, researchers found adherence rate of 86% in 2008
(Ukwe, Ekwunife, Udeogaranya, & Iwuamadi, 2010). Ekama et al. (2012)’s study within
the same period, 2009 -2010 showed 80.6% of participants had adherence rate greater
than 95%. This stands different from other studies but it is understandable as the study
was among pregnant women who are comparatively better adherence because of their
concern about their unborn baby (Ekama et al., 2012). More recent studies on adherence
to ARV in Nigeria show a comparatively better adherence (Akahara et al., 2017;
Olowookere, Fatiregun, Ladipo, Abioye-Kuteyi, & Adewole, 2015).
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Adherence Rates Among Adolescents
Adolescents have a disproportionate rate of HIV in sub-Saharan Africa as 80% of
the estimated two million adolescent aged 10-19 years living with HIV are from subSaharan Africa (Maskew et al., 2016). In HIV management, adherence at all stages of life
is important in ensuring good health outcome and also preserving the current HIV drug
treatment options because resistance is correlated to poor adherence (Coker et al., 2015).
Studies that involved this group have identified unique challenges associated with the
group in maintaining a good level of adherence. Challenges of adolescent and young
adult include puberty with attendant implications, sexual debut where escapades of
unhealthy sex become pronounced. HIV and STI acquisition also increase in the group
(Maskew et al., 2016). According to Maskew et al. (2016), among the adolescents (aged
12 - 20 years) that were enrolled into the prospective cohort study in South Africa, 38% (
n= 47) missed a clinic appointment within 24 months. Missing clinic appointment could
be a potential signal for a compromised adherence. The study revealed younger
adolescents below 15 years are more likely not to miss a clinic visit when compared with
the older ones who are 15 years and above.
Existing studies have shown a comparatively lower adherence rate among
adolescents and different reasons have been advanced for this (Xu, Munir, Kanabkaew, &
Le Coeur, 2017). Adolescent stage determines the trajectory of HIV management
globally as the stage serves as the transition from pediatric to adulthood as such the
adolescent is often without some defined health services as they are not considered to be
pediatric nor adult (Maskew et al., 2016). In a systematic review of adherence among
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adolescents of ages 10 – 19 years of age in Africa, four important themes emerged as
been common barriers to adherence to ART. These include impact from family structure,
nature of ARV regimen, urban versus rural location, and knowledge of HIV status and
gender (Hudelson & Cluver, 2015).
In Thailand, a study of adherence among perinatally infected adolescents was
carried out. The study used a cross-sectional survey data of 20 ART facilities including
urban, peri urban and rural and also did an in-depth-interview with adolescents and
caregivers (Xu et al., 2017). Multiple factors were enumerated as adherence inhibitors for
the adolescents. These included non-disclosure of sero-status which made it difficult for
the adolescents to adhere to their ARVs. Strained relationship with caregivers was
another reason for missing doses or not taking the ARVs at scheduled times. In addition,
forgetfulness because one was busy was another factor (Xu et al., 2017a). According to
Xu et al. (2017), younger age was related to sub-optimal adherence. This contradict the
study by Maskew et al. (2016) on younger adolescent (below 15 years) been relatively
more adherent than older ones. The Thailand study also had having a boy/girlfriend, selfreported unhappiness and frequent online chatting as adherence inhibitors. Other factors
influencing adherence negatively among adolescents in the study included not been
comfortable asking doctor questions and when a family member was the caregiver. Xu et
al. (2017) found 48% (n = 275) adolescents in the study was sub-optimally adherent
evidenced from rating of drug taking habit of participants by caregivers, missing doses as
self-reported and having the most current available HIV-RNA of greater than 1000
copies/ml.
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The studies by Maskew et al. (2016) in South Africa and Xu et al. (2017) in
Thailand among adolescent are quite relevant to my research focus. The stratification of
adolescents by age to assess their adherence by the two studies will also provide a basis
for me to stratify my study population to see if there is any variation in their respective
adherence before and after attaining a high CD4 count. The study population by the two
studies is focused on the same population of my interest, the adolescents.
Determinants of ART Adherence
A systematic review of 13 peer-reviewed articles on adherence to ART that were
published since the ART program began in Nigeria between 2002 and 2009 was carried
out. The reviewers searched for all published literature electronically using three key
search terms namely ‘adherence,' ‘ART,' and ‘Nigeria' (Monjok et al., 2010). Database
that were searched included PLoS Medicines, PubMed®, and ISI Web of Science®,
Science Citation Index® including all indexed journals on HIV/AIDS which involved
adherence to ART in Nigeria for the reviewed period. Several other sources were
explored for articles and these included HIV/AIDS foundations, international conferences
that focused on HIV/AIDS and websites of international organizations. Monjok et al.,
(2010) found that availability of ARVs was one of the commonest barriers to adherence.
Other obstacles included cost, stigma, alcohol abuse and transportation to the clinic. The
systematic review showed availability of ARV at HIV treatment center is a problem that
affects the hallmark of ART. Drug availability, therefore, improves the quality of care as
patients receive their prescribed medicines leading ultimately to improve health. Poor
adherence caused by unavailability of drugs has far reaching consequences which include
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impacting the virologic, immunological and clinical outcome of treatment (Monjok et al.,
2010). This is because a good adherence which is only achievable with available ARVs
decreases viral load, increase CD4 counts and in overall improves quality of life. The
mortality rate among HIV clients is also dependent on ARV availability. Research from
both Mkoka et al., (2014) and Kranzer and Ford, (2011) suggest ARV is, of course, the
center stage in the management of HIV/AIDS. The studies relate to my studies as the
dissertation work seek to explore adherence in AYA in Nigeria.
Adherence to ARV medicines is only realizable if they are available ARV when
needed by patients. The importance of the availability of ARVs in adherence in drug
management of HIV has been variously studied. In a research work in two ART clinics
one located in the rural area and the other in urban in southern Malawi, the perception of
eight healthcare providers on adherence to ART was explored (Mckinney, Modeste, Lee,
Gleason, & Maynard-tucker, 2014). Most of the patients in the two clinics were from
low-income and low-education backgrounds according to the studies. Mckinney et al.,
(2014) through the qualitative study found several barriers to adherence including
unavailability of ARVs, disclosure, and discrimination, side effects of medicines, belief,
and knowledge of ART outcomes, lack of access to food and shortage of staff. Another
study in Kinondoni Districts in Dar es Salaam in Tanzania, 20 health facilities were
investigated by Mori and Owenya, (2014). The 20 health facilities included 12 public
facilities, seven privates and a parastatal institution. Among these health facilities, 50%
of them were hospitals while the remaining 50% were primary health facilities. Mori and
Owenya, (2014) interviewed one person in charge of the facility and a member of
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pharmacy staff in each of the health facilities. The researchers found that of the 32,147
clients enrolled into care in the facilities, 20,831 (64.8%) were on ART, and there was
unavailability of ARVs in 16 out of the 20 facilities (80%). Out of the number, 10
facilities (62.5%) changed the regimens of 201 clients. Change of regimen is
recommended when there is a combination or any of the following; clinical failure,
immunological failure and/or virologic failure (WHO, 2010; WHO, 2015). The research
relates to my study as adherence to ARV is dependent on product availability at treatment
centers. Persistent unavailability of ARV could turn around to discourage patients from
keeping up prescription -refill appointments.
ART Adherence Inhibitors
Non-adherence has a lot of consequences which include impaired quality of life,
disease progression, medication waste, increased hospital visits, admissions and medical
resources (Jimmy et al., 2011). Researchers have revealed multiple factors that inhibit
adherence. In a cross-sectional study, assessment of factors influencing adherence to
ART in 261 patients in ART in Sulianti Saroso Infectious Disease Hospital in urban
Jakarta, Indonesia was carried out between August 2012 and November 2012 using
questionnaires to collect data (Weaver et al., 2014). In the study, 75% of the participants
were male with mean age of 33. 4 years, 54% were unmarried, 75% were Muslim among
whom 51% observed the religious fasting very year (Weaver et al., 2014). According to
Weaver et al. (2014), 77% reported been adherent to ART in the 90 days prior to the date
of interview. In the study, there was a correlation between adherence and level of social
support (p = 0.018) compare to poor social support. Reasons that were frequently
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provided for failing to take medicines included been asleep during medication time
(60%), forgetfulness (67%), and busy with something else (63%) (Weaver et al., 2014).
In a related research, 19 adolescents who have been minimum of six (6) months on ART
with age range of 12 – 19 years participated in a qualitative cross-sectional study to
assess adherence barriers and facilitators in Fever Unit of the Department of Medicines
and Therapeutics of the Korle-Bu Teaching Hospital, Ghana (Ankrah et al., 2016).
Among the participants, seven (7) were boys while 12 were girls. The identified
inhibitors of adherence among this age category included forgetfulness to take medicines
at the appropriate times, financial constraint, perceived stigma, and side effects of ART.
Frequently mentioned facilitators included support from health care worker (Ankrah et
al., 2016). Both (Weaver et al., 2014) and (Ankrah et al., 2016) studies share
demographics characteristics with my target population with respect to age and sociocultural environment. Also, the study design in both research is similar to my study.
Nyogea et al. (2015) carried out a research on determinants of adherence among
children and adolescents in Tanzania. The 116 participants aged 2 -19 years were
assessing ART care at Kilombero and Ulanga ARV Cohort, at the Chronic Diseases
Clinic Ifakara in St Francis Referral Hospital. Among participants who have been in care
in at least the previous 150 days before interview, 67 (58%) were males while the median
age for the participants was 9.8% (interquartile range: 5.7 – 13.3, range 2–19). The study
found average adherence of 84% among 70% of participants. The average adherence rate
from the research agrees with the findings of a research by Kim et al., (2014). The
quantitative analysis component of the mixed methods study did not show any
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association between adherence rates and CD4 + T cells counts, pill burden, WHO clinical
staging, socio-economic status, sex, duration on ART, disclosure status and education.
This study relates to my study as one of my research questions is to compare adherence
prior to attaining CD4 counts of 500 cells /mm3 and after the 500 cells /mm3. Also, the
study population, adolescent is my population of interest.
The perception of community members (irrespective of sero-status) and that of
health care workers as to what constitute adherence barriers for patients was explored
through focused group discussions in Zambezia Province in Mozambique. Groh et al.
(2011) employed phenomenology to understand the view of these categories as to what
they think constitute barriers to adherence for those taking ARV. They were 124
community participants (51.6% men) and 40 health care workers (16 female while 14
were male). In separate focused group discussions, several themes emerged. The common
ones that were identified as adherence barriers for those taking ART included economic
barriers which has to do with financial constraint in buying food and transportation to the
clinic. Patient-provider challenge was also listed. Community participants emphasized
there was absence of trust in the ability of health care workers to maintain confidentiality.
Poor treatment by hospital staff was also identified as an adherence barrier. Social barrier
mentioned included fear of stigma, fear of divorce and use of traditional healers (Groh et
al., 2011). The study is significant as I explored adherence among AYA in Benue State,
Nigeria.
Other barriers to ART adherence include religion and rituals, perception about
ART, substance misuse, industrial action, dissatisfaction with health services, and long
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patient wait time (Castro et al., 2015; Haberer et al., 2012; Kreitchmann et al., 2012;
Mayanja et al., 2013; Mckinney et al., 2014; Mepham, Zondi, Mbuyazi, Mkhwanazi, &
Newell, 2011; Nyamathi et al., 2012; Paschoal et al., 2014; Senkomago, Guwatudde,
Breda, & Khoshnood, 2011).
ART Adherence Facilitators
Among adherence facilitators, multiple factors have been identified. In Nepal, a
qualitative study used semi-structured questionnaire in a face-to-face interview to obtain
views of participants as to what constitute adherence facilitators. Through purposive
sampling, the researchers sampled 34 participants out of which 17 were health care
providers (doctors, nurses and pharmacists), three policy makers and 17 ART-prescribed
patients (Wasti et al., 2012). The identified themes included trusting health worker,
positive beliefs about ART and family and mechanical support. The findings
corroborated the study by Ekama et al. (2012) in Lagos Nigeria where HIV positive
women in a study of adherence assessment listed facilitators to adherence to include
desire to remain healthy, to have HIV-free children and the belief in the potency of
ARVs (Ekama et al., 2012).
Among people in Ethiopia, facilitators to adherence were identified as use of
reminders, desire to remain alive and raise children, improved health on ART, social
support, disclosure of HIV status, receiving adherence counselling (Bezabhe et al., 2014).
This was in a study in Felege-Hiwot Hospital and Gondar University Hospital in Ethiopia
where a total of 58 participants were part of the focused group discussion and semistructured interview between February 2013 and July 2013 (Bezabhe et al., 2014). In a
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meta-analysis study of adherence in sub-Saharan Africa, adherence rate was found to be
less than 80% among 23% of Africans (Croome et al., 2017). In a systematic review of
154 studies, 30 facilitators to adherence to ART were reported across sub-Saharan Africa.
These included social support (n= 60), good relationship with a health provider (n= 22),
disclosing HIV status (n = 26), reminders (n = 55), and healthier or feeling better after
taking ART (n = 22) (Croome et al., 2017).
Ankrah et al.(2016) studied 19 adolescents who have been on a minimum of six
months on ART with age range of 12 – 19 years through a qualitative cross-sectional
study to assess adherence barriers and facilitators in Fever Unit of the Department of
Medicines and Therapeutics of the Korle-Bu Teaching Hospital, Ghana. Among the
participants, 7 were boys while 12 were girls. Main facilitators of adherence included
support from health care providers and parental support. Just like Ekama et al.(2012)
found out in their research, patient’s knowledge of disease, self-motivation, patient’s
perceived positive outcomes, and dispensed formulation were other promoters of
adherence.
Measurement of Adherence
The importance of adherence has been elucidated in the preceding review
however, so much variations in adherence rates were observed even where adherence
measure was carried out in settings with similar characteristics (Akahara et al., 2017; Oku
et al., 2013, 2014). This can also be explained with the absence of a perfect adherence
measure as there is no gold measure of adherence (Lam, & Fresco, 2015). Some of the
tools that are used in measuring drug adherence can be categorized into objective and
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subjective measures. The former includes pill count, pharmacy refill, biological makers,
attendance log, electronic monitoring of medication administration such as medication
electronic monitoring system, secondary database analysis, and clinical outcome (Lyimo
et al., 2011; McMahon et al., 2011). Examples of subjective measures include family or
clinician report, patient interview and self-report (Chalker et al., 2010).
Other studies classified adherence measuring tools into direct and indirect
measures. Direct measures refer to measurement of drug metabolite in urine, blood or
body fluid to identify markers that were given with the drug. Measurement of drug
adherence using biological markers is considered the gold standard by some but this
measure also has its disadvantages (Modi, Ingerski, Rausch, Glauser, & Drotar, 2012).
Metabolic product is influenced by physiological state and metabolic rate. In addition,
drug plasma level differs for different individuals that took same drug at the same time.
Apart from been comparatively expensive, there is the white coat phenomenon where
patient takes the drug around clinic visit time (Modi et al., 2012). Another objective tool
is the electronic monitoring of medication administration. This adherence monitoring
devices is incorporated into drug prescription and it measures medication event such as
times bottle is opened. This tool comes in different forms and some of the features of this
tool include (i) recorded dosing events and stored records of adherence; (ii) audiovisual
reminders to signal time for the next dose; (iii) digital displays; (iv) real-time monitoring;
and (v) feedback on adherence performance (Lam et al., 2015). One of the assumptions
with medication electronic monitoring system is that each time a prescription bottle is
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opened, drug is administered but this is not always the case (Lyimo et al., 2011). The tool
is also comparatively very expensive hence its unpopularity in sub-Saharan Africa.
Pill count is an objective method that physically counts the number of pills during
clinic visit. Common way of calculating pill count which gives adherence ratio is using
the formula: Pill count = (Number of dosage units dispensed − number of dosage units
remained)/ (prescribed number of dosage unit per day × number of days between 2
visits). While this direct and objective measure is reliable, it is based on the same
assumption as medication electronic monitoring system (Lam & Fresco, 2015). An
unannounced phone pill count to assess adherence to pharmacotherapy in smoke
cessation found the pill count method to be very reliable to assess adherence to
medication (Thompson et al., 2011). A setback for the measure is absence of means to
verify time. Also, patient can decide to open and discard the pill before clinic visit to
appear to be following prescribed regimen (Jimmy & Jose, 2011). Patient self-report is
believed to the least reliable of all the methods yet the most used of all adherence
assessment tools because it is simple and cheap. It is done in several ways but the most
common is use of questionnaire where patient provide response to some questions. There
is clear absence of standard as questions are framed in different ways. The method has
high reliability but low specificity (Stirratt et al., 2015). Validity is a problem because
due to its prone to desire of respondents to appear adherent and memory bias could lead
to overestimation of adherence(Jimmy & Jose, 2011; Lam & Fresco, 2015). In a study in
Tanzania among ART patients in 2010, pharmacy refill, pill count, self-report and
adherence rates were all compared and pharmacy refill adherence less than 95% (<95%)
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emerged as the best method for predicting virologic failure (Sangeda et al., 2014b). The
study is related to my research work because I am going to use pharmacy refill as means
of assessing adherence. Also, in one of my research questions, I hope to look at changing
CD4 counts to see they could be predicted by adherence among adolescent and young
adult in Nigeria.
Health Facility Location and Adherence
Demographic characteristics of a people reflect in their adherence to medicines
from a plethora of studies on the concept of adherence (H. Kim, Kim, Bowman, & Cho,
2016; Magnabosco et al., 2015). Understanding factors behind adherence would help in
developing intervention that would remove or minimize such obfuscation. In HIV
management, adherence to ART among rural dwellers has been studied and likewise
urban dwellers. In Uganda, 1824 adolescents on ART in 30 different health facilities
were studied between December 2013 and February 2014. The cross-sectional study
made use of ART card to assess adherence to ART among participants (NabukeeraBarungi et al., 2015). The result showed adherence of greater than 95% among 90.4% (N
= 1588). Poor adherence to ART was independently associated with location of health
facility in rural area. According to Nabukeera-Barungi et al. (2015), outstanding factors
for poor adherence were stigma, discrimination and disclosure. This is quite
understandable as people in rural areas know each other better and the communal
lifestyle reduces confidentiality. However, a descriptive cross-sectional study of
adherence to ART among rural people in Nigeria found different reasons for non-
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adherence. Outstanding factors for non-adherence included being busy, forgetfulness, and
religious constraint (Oku et al., 2014).
Adherence among people in rural and urban dwellers has also been compared.
Distance to treatment center is said to be associated with adherence as those in rural areas
farther from treatment centers have been found to be comparatively less adherent (Yaya
et al., 2014). In South Africa (Eyassu, Mothiba, & Mbambo-Kekana, 2016); Nepal (Wasti
et al., 2012); Kenya (Wakibi, Ng’ang’a, & Mbugua, 2011); and Nigeria (Chineke, 2015;
Falang et al., 2012) researchers association between adherence and distance to treatment
centers. Reda and Biadgilign, (2012) and Heestermans et al.,(2016) corroborated this in
their systematic review of publications of articles on adherence to ART in Africa. Those
coming from father distance are said to be less adherent. What however is lacking in
literature is objective assessment of distance to treatment centers and adherence to ART.
All the studies are based on self-report questionnaires. Self-report was earlier mentioned
as a subjective form of adherence measurement (Chalker et al., 2010). These studies used
prospective cross-sectional methods, have adherence as their common outcome variables
like my studies. In addition, my study intends to further explore the issue of distance by
employing an objective study instead of the most common studies that have been based
on patient-report. Rather than a questionnaire, patient medical records will be used to
estimate distance to treatment center.
Adherence and Drug Resistance
Suffice to say the current availability of ARV is the hallmark of HIV/AIDS
management. In low and medium-income countries, there has been a surge in the number
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of people enrolled into ART care. In 2003, there were about 400,000 people enrolled into
care in sub-Saharan Africa and the number rose to 8 million in 2011 (Bosten et al., 2015).
Scale-up of ART in Africa correlates with a decrease in morbidity and mortality of cases
and likewise a decline in mother to child transmission. However, it is important to know
that the future of the current ARVs depend largely on adherence to ART. Unfortunately,
there is an emerging challenge with adherence as resistance to ARV has been linked to
poor adherence in some studies (Bosten et al., 2015). Acquired HIV drug resistance in
Africa relates with poor adherence and likewise viral load suppression is known to be
directly related to adherence (Castelnuovo, Sempa, Agnes, Kamya, & Manabe, 2011;
Kalichman et al., 2014). The UNAIDS has a vision to ensure 90% of those in care have
their viral load suppressed but this will remain a mirage in poor adherence.
In related research, Teklu and Yirdaw (2017) carried out a study on consequences
of ARV poor adherence and interruption in Ethiopia. Randomly selected ARV health
facilities in the country with a total of 22, 647 ARV patients were followed. The
longitudinal and retrospective cohort design covered the period between September 2005
and November 2013. There was treatment interruption of at least a month at some point
in 39% (8,759/22,647). Using Cox proportional hazards model, regression analysis was
carried out. Death for those who re-started treatment at the 6th, 12th, 18th and 24th months
was higher by 1.9, 2.4, 2.6 and 2.4 respectively compare to those who never had
interruption at those points. Finding from the research was that interruption was common
in Ethiopia. My study which is also going to be retrospective would equally use
regression analysis to explore the relationship between pharmacy refill among AYA.
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Findings from the Literature Review
A fair research work has been carried out on adherence to ARV medicines both in
developed and developing nations based on my findings. Adherence rates among several
studies differ and it is understandable as there is absence of a gold standard for adherence
measurement (Jimmy et al., 2011; Lam et al., 2015; Williams, Amico, Bova, & Womack,
2013). Most of the studies researched on the variables of my focus namely adherence,
CD4 counts, and factors that facilitate and inhibit adherence. Another striking thing is
majority of the studies are either prospective or retrospective cross-sectional studies with
most using patient self-report as measure of adherence. There is absence of study that
objectively examines adherence factor like distance from patient resident to treatment
center. All the studies as reviewed earlier used patient self-report. There is also absence
of studies that look at how adherence relates to CD4 when patient has high and low CD4
counts respectively. In addition, there is no literature available on association between
adherence when is detectable and when it turns undetectable. Lastly, studies that have
been identified only explored the influence of rural setting on adherence for patient
residing and accessing care in the same rural environment. My study intends to explore
the relationship between adherence and environment for those residing in rural setting but
accessing care in urban ART center.
Summary
In Chapter 2, TTM was used to understand stages of adherence as people initiate
and continue ART. Factors facilitating and inhibiting adherence have been revealed while
measures of adherence have been identified to include objective and subjective
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assessment tools. Distance to health facility that is well referenced as adherence inhibitor
is based on subjective assessment. What is however lacking, is the absence of using an
objective measure of adherence to draw a conclusion between adherence and distance to
the clinic. Also, there is no known study that attempts to compare adherence of patients
before and after CD4 counts dramatically improved. For example, from below 200
cells/mm3 to greater than 500 cells/mm3. These gaps are the areas of the focus of my
study. The next chapter will provide detail on methodology as it relates to data collection
and analysis to answer the research questions.
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Chapter 3: Research Method
Introduction
I developed this quantitative study to determine the following: (a) the difference
in adherence among AYAs accessing care in the same treatment center but resident in
different rural and urban settings, (b) the association between distance from treatment
center and adherence among AYAs, (c) the relationship between CD4 counts and
adherence among AYAs.
In this chapter, I describe how I secured approval from ethics committee of the
FMC Makurdi, the Walden University Institutional Review Board (IRB), and how the
secondary data from the FMC Makurdi in Benue State, Nigeria was collected. Further, I
offer a description of the sample population, and discuss sample size determination and
sampling procedure. I also discuss the statistical tests that I carried out in the course of
data analysis. Other areas of the study that I discuss in the chapter include threats to the
validity of the study, ethical procedures, and data operationalization.
Research Method and Rationale
This was a retrospective, cross-sectional, descriptive, quantitative study (see
Creswell, 2009; Gordis, 2009). I used secondary data from the Federal Medical Center
located in Makurdi, Benue State, Nigeria. I chose the cross-sectional method for the study
because I sought to establish a relationship between the variables involved without
establishing causality (Campbell & Stanley, 1963; Frankfort-Nachmias & Nachmias,
2015; Mann, 2003). The design was appropriate for my study because my goal was to
explore the relationship between adherence rates, CD4 counts, environment, and distance
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to treatment center among AYA in Nigeria. Also, the method was comparatively cheap,
and since I had no sponsorship, I could not afford an expensive research project given my
personal resources.
The data for the research was collected at a particular point in time, which made
the cross-sectional study ideal. Merits of cross-sectional study are numerous, and include
a provision of data for odds ratio, absolute risks, and relative risk from prevalence
(Thompson et al., 1998). Multiple outcomes, along with exposures, could also be
concurrently explored using a cross-sectional study, and one does not need to follow up
with participants, making it ideal for a descriptive study (Thompson et al., 1998). Also,
the influence of a researcher in a quantitative study is minimal, and result from the
method are generalizable when they are based on the larger population (Polit & Beck,
2010). Disadvantages of the study approach include a potential for misclassification
because of bias, and inability to distinguish which comes first between exposure and
outcome. I used both independent t test and ANOVA in the data analysis to explore
differences between variables, and carried out bivariate analysis to assess association.
These statistical tests are ideal for a study that has a continuous dependent variable and
categorical or continuous predictor variables (Hellevik, 2009; Schneider, Hommel, &
Blettner, 2010).
I used the TTM to explain differences in adherence relating to the independent
variables such as CD4 counts, environment, and distance to the treatment center. The
theory has been used widely in the study of patient health behavior change programs like
those for physical exercise, diet adherence, and smoking cessation (van Leer et al.,
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2008a). Recently, the theory has gained popularity for understanding adherence to
medicines (Johnson et al., 2006).
Methodology
Study Area and Population
This study began with a definition of my study area and population alongside
determination of sample size. Data for the study was collected from the FMC located in
Makurdi, Benue State, Nigeria. Makurdi is the capital of Benue State, which is located in
the Middle-Belt region of Nigeria. The state had a population of 4.2 million in the last
census conducted in 2006 (National Population Commission, n.d.). The land mass is 33,
955 square kilometers and lies between Latitudes 6.5° and 8.5° N and Longitudes 7.47° E
and 100 E, and is accessible by road (Goon et al., 2011). There are 21 local government
areas in the state, which is surrounded by Cross River, Ebonyi and Enugu States to the
south; Kogi State to the west; Nasarawa State to the north; and Taraba State to the east.
The state also shares an international boundary with the Federal Republic of Cameroon
on the southeast flank. It is an agrarian state made up of two major tribes namely Tiv and
Idoma, with Igede. And Etulo as minority tribes. Most of the inhabitants are farmers and
are mainly Christians with a few idol worshippers (Akaakohol & Aye, 2014). Because
the health facility is a referral center, it serves populations from the surrounding states as
well.
Population
The population of interest in the study was composed of AYAs enrolled in HIV
treatment in the FMC Makurdi, Benue State in Nigeria. I selected this tertiary hospital for
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the study because it has a large population of ART clients. The large population could be
due to the quality of care, and size and accessibility of Makurdi, which is accessible by
road, rail, and water (Goon et al., 2011).
Sample Size
In research, it is not always feasible to study the entire population, hence the use
of sample size. Appropriate sample size determination is significant because it helps to
identify relevant differences in studies. For sample size determination, there are many
methods and formulae available, including the web-based G*power which requires
imputation of the desired parameters depending on the statistical test. Factors to consider
while deciding on which method to use in sample size calculation include the nature of
the variables and whether they are categorical or continuous (Altman & Royston, 2006;
Turner, Dobson, & Pocock, 2010). Beside the desired power, marginal error and the level
of significance are other factors to consider (Suresh, Thomas, & Suresh, 2011; Suresh &
Chandrashekara, 2012). The relationship among variables also influences the method of
sample size calculation and the statistical test a researcher intends to employ in the
analysis.
For my study, which was descriptive, the Leslie and Kish formula was applied
(Eng, 2003). The formula for sample size calculation was:
n=

𝑍2 𝑝 𝑞
𝛿2

In this equation, n equals the sample size required. Z is the critical value that
corresponds to the selected significance criteria (significance level or level of alpha) and
confidence interval (CI) obtained from the statistical table. At 95% CI, the value obtained
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is 1.96. The abbreviation p marks the proportions of the attribute in the population under
investigation. Several studies in Nigeria have a different prevalence for the proportion of
ART clients that is 100% adherent. The range is between 31.2% and 91% (Akahara et al.,
2017; Bello S.I, 2011; Ekama et al., 2012; Lawan, Amole, Gambojahun, & Eneabute,
2015; Pennap et al., 2013). I used the proportion from a descriptive cross-sectional study
of adherence to ART among HIV-infected adolescents in Kano, Nigeria. The proportion
of adherent adolescents was 90.5% (Lawan et al., 2015). So, in this study, p = 0.905
(90.5%). Delta (δ) equals the total width of the expected CI (marginal error), and I made
an assumption of 0.025 (2.5%). That is the level of precision taken: Q = 1 – p.
Substituting these in the formula above, it becomes:
n = 1.962 *0.95 (95%) (1 – 0.905) / 0.0252 = 528
Adding a 10% gives required sample size of 581. The 10% was added in case of
incomplete data from some patients’ files. However, the sample size that I collected and
included in the analysis was 656.
Sampling and Sampling Procedure
I sampled the available secondary data to get a subset (sample) of a population of
interest (Chava Frankfort-Nachmias & Leon-Guerrero, 2015). I used purposive sampling,
which is a non-probability type of sampling (Palinkas et al., 2015), so as to get samples
that have variables of interest which included CD4 counts result, pharmacy refills, and
physical contact address (distance and location). From the medical records, files (hard
copy) of clients were pulled out and reviewed, and only patients with variables of interest
were selected. The process continued until the sample size of 656 was reached.
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Inclusion and Exclusion Criteria
To be included in the study, participants must have met the following criteria:
•

Must be HIV seropositive because the outcome of interest is about adherence
among participants who are HIV seropositive.

•

Must be between ages 15 and 24 years because the study group is for AYA
between these ages.

•

Must have started ART within the study period of 2010-2016. This is to
observe how CD4 relates to adherence as patients continue in care.

•

Must be enrolled in care at the FMC Makurdi

Exclusion criteria included:
•

Any patient below 15 years of age or above 24 years of age because the study
population included only those within ages 15–24 years.

•

Any patient not enrolled in ART in the FMC Makurdi. This was because this
was where I obtained ethical clearance for the study.

•

Any patient who enrolled in ART care within the study period but had been on
ART elsewhere. This was because of potential for such patients to have high
CD4 count.

•

Any client that is not HIV seropositive because the outcome of interest was
for clients who are on ARV.
Gaining Access to the Data Set

From my previous personal work experience (former employee of the FMC
Makurdi), I knew my variables of interest were captured in patient’s medical records in
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the FMC Makurdi. However, to be sure nothing had changed, I wrote an email to a staff
member at the FMC Makurdi who confirmed that the variables of interest were still
captured in patients’ files. With the background knowledge, I wrote an application letter
to the ethics committees of the FMC Makurdi and requested ethical approval to access
patient data (see appendix A). Once my proposal was approved, I submitted the study
proposal to the Walden University Institutional Review Board (IRB) to ensure the study
complied with the university’s ethical standards. With approval from Walden’s IRB
(approval number 10-19-17-0434421) data was collected in line with my study protocol
(see Figure 4). Collected data was saved on my laptop, was pass-word protected, and will
be destroyed after 5 years.
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Figure 4. Data extraction process.
Operationalizing Variables
The independent variables in the study included: CD4 cell counts (cell/mm3); the
location of patient's residence (urban/rural); and distance from the treatment center. The
dependent variable in the study was be adherence rate. For the study, adherence rate of
≥85% was considered good adherence while adherence rate of <85% was deemed
suboptimal or poor adherence. Adherence rate which refers to the extent patient drug
taking behavior corresponds with what was collectively agreed with the health care
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provider was based on pharmacy refill. It was calculated using the formula (Olowookere,
Fatiregun, Akinyemi, Bamgboye, & Osagbemi, 2008):
Adherence rate is equal to difference between number of expected pharmacy refills and
number of missed pharmacy refills divide by expected number of pharmacy refills and
multiply by 100%.
Covariates in the study were sociodemographic data which will included; age;
gender; marital status (married, widowed separated, and single); employment (employed,
unemployed, farming and business persons); the number of years in treatment (expressed
in years); and educational level (no education, primary school, secondary school and
post-secondary school). These covariates were identified based on previous studies where
they have been found to influence adherence individually (Jobanputra et al., 2015;
Mayanja et al., 2013; Shigdel et al., 2014; Yaya et al., 2014).
Independent t-test and ANOVA were used in the analysis since the outcome of
interest, adherence rate was continuous variable. Variables were coded as Adherence
(ADH); CD4 counts (CD4T); distance to the ART center (DART); while environment
(SETN) was either rural or urban. For the demographic data: age (AGE); gender (GEND)
was be male, female; employment (EMPL) was be grouped as employed, unemployed,
farming and business person. Unemployed' (including those working but not salaried).
The number of years (YERS) since enrollment was categorized into less than five years
(< 5 years) and greater than five years (≥ 5 years). Marital status (STAT) was grouped
into married, widowed, single and separated (Separated would include divorced).
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Education (EDUC) was coded into no education, primary education, secondary education
and post-secondary education.
Data Collection
With approval from the ethical committee of the FMC Makurdi and Institutional
Review Board in Walden University, I recruited two clinical staff from the FMC
Makurdi, provided them with the orientation to support in extracting the needed data
from patients’ medical records in line with the sampling method for the study.
The secondary data from and the FMC Makurdi were originally collected from
clients who were enrolled into ART. Treatment and care from the hospital for HIV is free
as a result of the fund from President's Emergency Plan for AIDS Relief (PEPAR) by the
United States Agency for International Development (USAID) (Oku et al., 2013). There
were various points where these biodatas were collected from clients during enrolment
into ART, and these included at the patient registration point, laboratory unit,
adherence/counseling unit, and pharmacy unit. All the information captured went to a
single file and saved in the medical records department of the hospital. Therefore, gaining
access to patient medical records we were able to easily extract variables that were of
interest to me. The variables of interest were extracted and saved in an excel format passworded. After it was cleaned, the data was imported into SPSS v24.0 for data analysis.
Codebook
I created a codebook. The book contains names of all the variables, variable
labels, value labels, and it also shows changes that were made such as fixing raw
variables or creating new variables (Moreno, Egan, & Brockman, 2011). It helped me
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throughout the analysis in getting confused in the course of data analysis and also
provided a guide in interpreting data analysis result.
Data Cleaning
After the data was collected with the support of the research assistants, I manually
cleaned the data. With the support of the two supporting clinical staff, we were able to
trace patients with missing contact address in the main hospital registration records. Also,
variables that were missing and could unnecessarily skewed the analysis were not
included in the analysis.
Data Analysis Plan
I performed a univariate analysis on the study sample to provide descriptive
statistics for all the variables. For categorical variables, appropriate descriptive statistics
included pie and bar charts, frequencies, and percentages. For the continuous variables
the appropriate descriptive statistics included histogram, measure of dispersion or
variation (range, variance, and standard deviation), measures of central tendency (mean,
median, and mode) and normality statistics such as Kurtosis and Skewness (Larson,
2006) depending on the data. Then Pearson correlation was carried out to test for
correlation between adherence and each of the predictors. Where the p value less .05, the
null hypothesis was rejected. Where the null hypothesis was rejected, a bivariate
regression was performed ANOVA to test for the overall significance of the correlation.
Descriptive statistics was also be carried for the demographic data including age, gender,
marital status, employment, the number of years in treatment, and education and figures
and tables will be presented (Hidalgo & Goodman, 2013).
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Independent t-test was used to assess the difference in adherence to ART
medicines between patients in urban and those who resided in rural areas. Several other
comparisons using t-test were carried out to test for statistical significant difference in
adherence rate to ART and these included adherence rate by gender; between ages 15 and
19 years and 20 and 24 years; between those who have been on ART for less than 5 years
and those who have been on ART for at least five years; between those with CD4 counts
of ≥ 500 cell/mm3 and those with <500 cells/mm3; between those who lived ≤ 50
kilometers away from the hospital and those that lived > 50 kilometers away from the
hospital. In order to test for any statistical significant difference in adherence rate based
on level of education, marital status, distance to the hospital and employment, ANOVA
was performed. This was because these variables have more than two categories and the
dependent variable is an interval-ratio level of measurement. See Figure 5.
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Descriptive statistics
(frequencies, percentages and tables)

Inferential statistics
(e.g. linear regression)

Inference, decisions and
conclusion

Figure 5. Summary of data analysis.
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Analysis of Research Questions and Hypotheses
I conducted data analysis to answer the following three research questions:
RQ1: What is the difference in adherence to ART among AYA accessing ARV
medicines in the same treatment center but residing in rural and urban settings?
Ho1: There is no statistically significant difference in adherence to ART among
AYA accessing ARV medicines in the same treatment center but residing in rural and
urban settings
Ha1: There is statistically significant difference in adherence to ART among
AYA accessing ARV medicines in the same treatment center but residing in rural and
urban settings
RQ2: What is the association between distance from treatment center and
adherence to ART among AYA?
Ho2: There is no statistically significant association between distance from
treatment center and adherence to ART among AYA
Ha2: There is statistically significant association between distance from treatment
center and adherence to ART among AYA.
RQ3: What is the relationship between a high CD4 counts (> 500 cell/mm3) and
adherence to ART among AYA?
Ho3: There is no statistically significant relationship between a high CD4 counts
(> 500 cell/mm3) and adherence to ART among AYA.
Ha3: There is statistically significant relationship between a high CD4 counts (> 500
cell/mm3) and adherence to ART among AYA
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For RQ1, because the question seeks to evaluate the difference in adherence rate,
t-test was employed. It was used to test for the difference in adherence between
participants resident in rural and urban settings but accessing care in ART clinic in the
FMC Makurdi. The effect size of the difference was calculated using Cohen’s d. When
the t-test is large the bigger is the difference in adherence between the two groups and the
more significant the result which makes it easier for the null hypothesis to be rejected.
From the SPSS result, effect size was estimated by calculating Cohen’s d value from the
formula:
Cohen’s d = (M2 -M1)/SDpooled
SDpooled = √(SD12 + SD22)/2
M1 = Mean difference of adherence for participants resident in urban setting
M2 = Mean difference of adherence for participants resident in rural setting
SD1 = Standard deviation for adherence among urban participants residents
SD2 = Standard deviation for adherence among rural participants residents

For RQs 2 and 3, the questions seek to explore the association between the
predictors and the outcome. As a result, a correlation and bivariate tests were performed
between adherence rate to ART and distance to the hospital while linear regression was
the statistical model that was used to predict the relationship between adherence rate and
distance to the hospital. Correlation test was also performed between high CD4 (≥ 500
cell/mm3) and adherence rate to ART and a low CD4 counts (< 500 cell/mm3) adherence
rate. In order to test for a difference in adherence rate between the two sub groups of CD4
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(≥ 500 cell/mm3 and < 500 cell/mm3), the independent t-test (two-tailed) was employed.
The acceptable significance level (α) will be set at .05. If the p-value is < .05, the null
hypothesis (Ho) will be rejected while the alternative hypothesis will be accepted.
Threat to Validity
The validity of a research determines if the research truly measures what it was
set to measure from the beginning (Nahid Golafshani, 2003). However, in a practical
sense, there could be a threat to accomplishing the goal of validity. In my research,
secondary data was used, and it comes with limitations such as the challenge in
constructing validity, missing data, an absence of some variables. Missing data could
make the generalization of such research inaccurate. Also, because the data sample was
purposively sampled, external validity, that is generalizing findings from the study will
be impacted. The study period was about five years ago; it is possible some structural and
functional changes have occurred in the treatment and management of HIV clients in
Benue State. The cross sectional nature of my research also makes generalization limited
to sampled population (Chava Frankfort-Nachmias & Leon-Guerrero, 2015).
Ethical Procedures
In carrying out research, there is a basic ethical principle as outlined in principles
of Belmont Report that has to be followed because research involves human subjects and
these principles include respect for persons, beneficence, and justice (The Belmont
Report, n.d.). Respect for persons implies participant in research should be accorded
respect and individuals with diminished autonomy are entitled to protection while in
addition to respecting decisions of participants and protecting them efforts have to be
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made to secure their well-being (The Belmont Report, n.d.). It is the hallmark of the
principle of beneficence. Because I made use of secondary data, the issue of obtaining
informed consent from participants would not arise, but approval was still obtained from
the IRB and the ethics committee the FMC Makurdi. After receiving letter of cooperation
from ethics committees of the FMC Makurdi, and IRB, I proceeded to obtain the
secondary data. With the two approvals (FMC Makurdi and IRB Walden), a copy of the
dissertation will be shared with the FMC Makurdi before embarking on the publication of
my research findings. Any variable capable of identifying a participant such as patient
identification numbers were excluded from analysis. Also, data was saved and passworded.
Post Data Analysis
Once data analysis has been completed, and study officially ended, data on my
laptop will be permanently deleted after 5 years.
Summary
The study was a retrospective cross-sectional study design where adherence rate
for AYA in Benue State in Nigeria was analyzed. Secondary data from the FMC Makurdi
was used. T-test was performed to explore the difference in adherence between city and
urban dwellers accessing care in the same ART treatment center. Other statistical tests
used included bivariate analysis, ANOVA and linear regression (Greenland et al., 2016).
The chapter provided an overall in depth on the methodology of the study. In Chapter 4,
the result of the study was analyzed and discussed.
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Chapter 4: Results
Introduction
I conducted this study to explore (a) any difference in ART adherence rates
among AYA who resided in rural or urban setting and access care in an urban treatment
center, (b) the association between distance to a treatment center and adherence rate to
ART, and (c) the relationship between a high CD4 (≥ 500 cell/mm3) and adherence.
According to the literature, factors that influence adherence include distance to ART
treatment center, environment (urban/rural), age of patient, and duration of treatment, as I
discussed in Chapter 3. As of November 2017, no researchers have studied adherence to
ARV medicines in relation to these mentioned variables among AYA in Benue State,
Nigeria. In the study, I was therefore, guided by the following RQs and hypotheses:
RQ1: What is the difference in adherence to ART among AYA accessing ARV
medicines in the same treatment center but residing in rural and urban settings?
Ho1: There is no statistically significant difference in adherence to ART among
AYA accessing ARV medicines in the same treatment center but residing in rural and
urban settings
Ha1: There is statistically significant difference in adherence to ART among
AYA accessing ARV medicines in the same treatment center but residing in rural and
urban settings
RQ2: What is the association between distance from treatment center and
adherence to ART among AYA?
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Ho2: There is no statistically significant association between distance from
treatment center and adherence to ART among AYA
Ha2: There is statistically significant association between distance from treatment
center and adherence to ART among AYA.
RQ3: What is the relationship between a high CD4 counts (> 500 cell/mm3) and
adherence to ART among AYA?
Ho3: There is no statistically significant relationship between a high CD4 counts
(> 500 cell/mm3) and adherence to ART among AYA.
Ha3: There is statistically significant relationship between a high CD4 counts (>
500 cell/mm3) and adherence to ART among AYA.
In Chapter 4, I discuss data collection and present the result of the study. Results,
analysis, and findings on adherence to ART among AYA in Benue State, Nigeria was
based on the use of different statistical tools. I used descriptive and inferential tests,
which I present in the chapter. The data collected, though constrained by the nature of the
cross-sectional study design, is a representation of the general population in Benue State,
Nigeria that accesses ART at the FMC Makurdi. The total sample size (n = 581) was
needed for my study. However, a sample size (n = 656) that surpassed what was
originally planned was used.
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Data Collection
After ethical clearance from the Ethics Committee of the FMC Makurdi, I
collected data on patients who attended the ARV clinic of the hospital for between 2010
and 2016. This was done with the support of two clinical support staff members at the
hospital. There was no need to obtain informed consent because I used secondary data. I
sequentially followed the serial numbers in the enrolment register to obtain the first 656
patients who met the inclusion criteria as outlined in Chapter 3. The data was deidentified at the point of collection where all identifiable information was deleted.
Results of the Study
In the following subsection, I present the results of the analyses.
Descriptive Statistics for the Study Population
Categorical variables. The study had a population of (n = 656) and most were
females (n = 590, 89.9%). Males comprised only 10.1% of the population (n = 66; see see
Table 2).
Table 2
Descriptive Statistics by Gender

Valid

Frequency

Percent

Female

590

89.9

Valid percent Cumulative
percent
89.9
89.9

Male

66

10.1

10.1

Total

656

100.0

100.0

100.0
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The unemployed constituted a largest population the group (n = 251, 38.3%),
while about one-third were farmers (n = 204, 31.1%). Others were either employed (n =
14, 2.1%) or business owners (n = 82, 12.5%). Types of businesses included selling
oranges, operating hair dressing salons, roadside electrical work, fuel dealing, upholstery
work, food vending, clothes tailoring (seamstress), clothes sales, and the like. For the
employment status variable, the data was missing for 105 participants (16%; see Table 3).
Table 3
Descriptive Statistics by Employment Status
Cumulative
Frequency

Percent

Valid Percent Percent

Unemployed

251

38.3

45.6

45.6

Employed

14

2.1

2.5

48.1

Business person 82

12.5

14.9

63.0

Farming

204

31.1

37.0

100.0

Total

551

84.0

100.0

Missing -99

105

16.0

Total

656

100.0

Valid

The level of education among the study population also varied, with the largest
having only secondary education (n = 238, 36.3%) while the least was those with tertiary
(post-secondary) education (n = 48, 8.6%). Others included those with primary education
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(n = 185, 28.2%) and those who have never been to school or did not complete primary
school (n = 87, 13.3%). Missing data for the category was (n = 98, 14.9%) (see Table 4).
Table 4
Descriptive Statistics by Education
Cumulative
Frequency

Percent

Valid Percent Percent

None

87

13.3

15.6

15.6

Primary

185

28.2

33.2

48.7

Secondary

238

36.3

42.7

91.4

Tertiary

48

7.3

8.6

100.0

Total

558

85.1

100.0

Missing -99

98

14.9

Total

656

100.0

Valid

A majority were married (n =245, 37.3%), single (n = 228, 34.8%), divorcees (n
= 7, 1.1%) and those that separated from their spouses (n = 43, 6.6%) had the least
population. Missing data accounted for (n = 98, 4.9%) (see Table 5).

81
Table 5
Descriptive Statistics by Marital Status
Cumulative
Frequency

Percent

Valid Percent Percent

Single

228

34.8

40.9

40.9

Married

245

37.3

43.9

84.8

Divorced

7

1.1

1.3

86.0

Widowed

35

5.3

6.3

92.3

Separated

43

6.6

7.7

100.0

Total

558

85.1

100.0

Missing -99

98

14.9

Total

656

100.0

Valid

A higher proportion of the study population resided in urban areas (n = 275,
41.95%), while those in the rural areas constituted 23.3% (n = 153). Missing data was (n
= 228; 34.8%). See Table 6.
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Table 6
Descriptive Statistics by Environment
Cumulative
Percent

Valid Percent Percent

41.9

64.3

64.3

23.3

35.7

100.0

65.2

100.0

34.8
100.0
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Summary of the descriptive statistics for the categorical variables is displayed in Table 7
Table 7
Summary Descriptive Statistics for the Categorical Variables
Employment

N

Valid

Gender

status

Education Marital status Environment

656

551

558

558

428

105

98

98

228

Missing 0

Continuous variables. Adherence rate: The mean, median and mode were 92.05,
100 and 100 respectively. The standard deviation (SD = 14); kurtosis was -2.68 and
Skewness was 8.77 while the maximum and minimum values were 100 and 9
respectively with a range of 91. Final CD4 count: The highest CD4 was 1356 cells/mm3
while the lowest was 10 cells/mm3. The mean and standard deviations were respectively
M = 568.48, SD = 274.39. Those with a CD4 less than 500 cell/mm3 were 188 (28.7%)
while 250 (38.1%) had a CD4 count at least 500 cell/mm3. A third of the data, 218
(33.2%) was missing. The six CD4 count values are displayed in Table 8. With respect to
age, M = 21.37, SD = 2.42. Those between the age bracket 15 and 19 were 109 (16.6%)
while about two – third, 413 (63%) was between ages 20 and 24 years. Missing data
accounted for one -fifth, 134 (20.4%). Distance to the hospital: The maximum distance
from the hospital was 306 kilometers while the minimum was 2 kilometers. M = 51.58,
SD = 55.29. Half of the study population, 329 (50.2%) lived at most 50 kilometers away
from the hospital where they received ART. Those between 51 and 100 kilometers away
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from the hospital were 88 (3.4%) while those between 101 and 150 kilometers were 56
(8.5%). A total of 36 (5.5%) participants lived between 151 and 200 kilometers whereas
2 (.3%) participants lived between 201 and 250 kilometers. Participants that lived
between 251 and 300 kilometers were 2 (.3%) while 1 participant lived between 301 and
350 kilometers away from the hospital. Missing data accounted for about a fifth, 142
(21.6%). Duration on ART: M = 2.99, SD = 3.92. The duration on ART among the study
population shows those less than 2 years were 244 (37.2%); those between 2.01 and 4.00
years were 163 (24.8%). Ages 4 – 6 years were 229 (34.9%) while those who have been
on ART between 6.01 and 8.00 years were 15 (2.3%). Missing data was 5 (0.8%). See
Tables 8 - 13 for details.
Table 8
Mean CD4 Values

N

Mean

Valid
Missin
g

First CD4
Second
Third CD4 Fourth CD4 Fifth CD4 Sixth CD4
value
CD4 value
value
value
value
count
645
509
591
550
475
438
11
147
65
106
181
218
320.41

400.35

418.39

454.83

504.75

568.48
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Table 9
Adherence rate Statistics

N

Valid

652

Missing

4

Mean

92.05

Median

100.00

Mode

100

Std. Deviation

14.030

Variance

196.828

Skewness

-2.678

Std. Error of Skewness

.096

Kurtosis

8.770

Std. Error of Kurtosis

.191

Range

91

Minimum

9

Maximum

100

Sum

60017
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Table 10
Descriptive Statistics for CD4 Count (Categorized)
Cumulative
Frequency

Percent

Valid Percent Percent

0-499

188

28.7

42.9

42.9

500 – 1500

250

38.1

57.1

100.0

Total

438

66.8

100.0

Missing -99

218

33.2

Total

656

100.0

Valid

Table 11
Descriptive Statistics for Age
Cumulative
Frequency

Percent

Valid Percent Percent

15 -19

109

16.6

20.9

20.9

20 – 24

413

63.0

79.1

100.0

Total

522

79.6

100.0

-99

134

20.4

Total

656

100.0
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Table 12
Descriptive Statistics for Distance
Cumulative
Frequency

Percent

Valid Percent Percent

0-50

329

50.2

64.0

64.0

51-100

88

13.4

17.1

81.1

101-150

56

8.5

10.9

92.0

151-200

36

5.5

7.0

99.0

201-250

2

.3

.4

99.4

251-300

2

.3

.4

99.8

301-350

1

.2

.2

100.0

Total

514

78.4

100.0

Missing -99

142

21.6

Total

656

100.0

Valid

88
Table 13
Descriptive Statistics for Years on ART
Cumulative
Frequency

Percent

Valid Percent Percent

0-2.00

244

37.2

37.5

37.5

2.01-4.00

163

24.8

25.0

62.5

4.01-6.00

229

34.9

35.2

97.7

6.01-8.00

15

2.3

2.3

100.0

Total

651

99.2

100.0

Missing -99.00

5

.8

Total

656

100.0

Valid
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Table 14
Descriptive Statistics for the Continuous Variables
Minimu Maximu

Std.

N

Range m

m

Sum

Mean

Deviation

Years on ART

656

6.41

.00

6.41

1962.92 2.9923 1.98037

3.922

Age

656

9.39

15.01

24.40

14019.74 21.3716 2.42174

5.865

Adherence rate 652

91

9

100

60017

92.05

196.828

CD4 count

438

1346

10

1356

248996

568.48 274.387

75288.131

Distance to

514

304

2

306

26511

51.58

3056.650

14.030

55.287

Variance

hospital
Valid N

356

(listwise)

Statistical Analyses
Research Question 1
RQ1: What is the difference in adherence to ART among AYA accessing ARV
medicines in the same treatment center but residing in rural and urban settings?
Ho1: There is no statistically significant difference in adherence to ART among
AYA accessing ARV medicines in the same treatment center but residing in rural and
urban settings
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Ha1: There is statistically significant difference in adherence to ART among
AYA accessing ARV medicines in the same treatment center but residing in rural and
urban settings
T-test analysis. For assessment of the difference in adherence to ART medicines
between patients in urban and those who resided in rural areas, t-test analysis was carried
out. Assumptions that must be taken into consideration while using t-statistics include the
variable having a discernible distribution that approximate normal and the grouping
variable is categorical and dichotomous (Field, 2013). The assumption of discernible
distribution was violated (Skewness = - 2.678; kurtosis = 8.770) as a result the data was
transformed for the purpose of conducting a t-test (i.e. skew < |2| and kurtosis < |9|
(Schmider, Ziegler, Danay, Beyer, & Bühner, 2010). However, a t-test analysis with the
transformed data gives a result that was similar when the data was untransformed. As a
result, I present the results with the untransformed data which also makes the
interpretation of the result less complicated. The independent t-test (two-tailed) was used
and the SPSS output is shown in Table 15.
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Table 15
Independent Samples Test for Adherence rate and Environment
Levene's Test
for Equality of
Variances

t-test for Equality of Means

Mean

Std.

95% Confidence

Error

Interval of the

Sig. (2- Differen Differen Difference
F
Adherenc Equal
e rate

variances

Sig.

T

Df

tailed) ce

ce

Lower Upper

14.568 .000

-

424

.001

-4.661 1.421

-7.455 -1.868

419.0 .000

-4.661 1.249

-7.117 -2.206

3.280

assumed
Equal

-

variances not

3.731 33

assumed

Adherence rate to ART for those who lived in urban settlements (N = 274) was M
1

= 89.42 (SD1 = 15.909). Comparatively, those in rural settlements (N = 152) had

adherence rate M 2 = 94.08 (SD2 = 9.843). In order to test for the hypothesis that there is
statistically significantly difference in adherence rate to ART between the population in
urban and rural settlements, I performed an independent t-test. Levene’s test for equality
of variance was examined. The key assumption in this test is that the variances for both
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categories of patients are equal (Anderson, Burnham, & Thompson, 2000). Therefore, we
test for equal variance assumed. The t-test result showed statistically significant
difference in adherence rate to ART between those who lived in urban and rural
settlements, t (424) = -3.280, .001, p < .05. Therefore, we failed to accept the null
hypothesis that there is no significant difference in adherence rate to ART between urban
and rural population.
In order to understand and appreciate the effect size of the difference, Cohen’s d
was estimated as follows:
Cohen’s d = (M 2 - M 1)/SDpooled
SDpooled = √(SD12 + SD22)/2
M 1 = Mean difference of adherence for participants resident in rural setting = 89.42
M 2 = Mean difference of adherence for participants resident in urban setting = 94.08
SD1 = Standard deviation for adherence among rural participants residents = 15.909
SD2 = Standard deviation for adherence among urban participants residents = 9.843
d = .4923. This is approximately .5. The scale for Cohen’s d is small (d = 0.2), medium
(d = 0.5), and large (d ≥ 0.8). This implies the mean variance between the adherence rates
of patients in rural and urban setting is of moderate effect (Sullivan & Feinn, 2012).
Several other comparisons using t-test were carried out to test for statistical
significant difference in adherence rate to ART and these included adherence rate by
gender where there was no statistically significant difference between male and female, t
(650) = .066, .947, p >.05. Between ages 15and 19 years and 20 and 24 years, there was
no statistically significant difference, t (518) = .304, .761, p > .05. With respect to
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duration on therapy, between those who have been on ART for less than five and those
who have been on ART for at least five, t (650) = 1.830, .068, p > .05. There was
however, a statistically significant difference between those with CD4 counts of at least
500 cell/mm3 and those with less than 500 cells/mm3, t (436) = -2.819, .005, p < .05 with
a Cohen’s d value of .38. i.e. approximately .4. A statistically significant difference was
also observed between those who lived at most 50 kilometers away from the hospital and
those that lived more than 50 kilometers away from the hospital, t (509) = -2.37, .018, p
< .05 with Cohen’s d value of 0.044 (Approximately .04).
In order to test for any statistically significant difference in adherence rate based
on level of education, marital status, distance to the hospital and employment, ANOVA
was performed. This was because these variables have more than two categories and the
dependent variable is an interval-ratio level of measurement (Frankfort-Nachmias, C., &
Leon-Guerrero, 2015).
Education: For education, the result of the ANOVA analysis is displayed in Table
16. The mean difference to adherence rate between groups was statistically significant (F
= 7.2, p <.000). Therefore, the null hypothesis that there was no statistically significant
mean difference between the groups was rejected.
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Table 16
ANOVA by Adherence Rate Based on Education Level

Sum of
Squares

Df

Mean Square F

Sig.

Between groups

3851.552

3

1283.851

.000

Within groups

97826.055

551

177.543

Total

101677.607

554

7.231

Since there was a statistically significant mean difference between the two groups,
post-hoc was used to explore if there was any variance within the group. The Levene’s
test for homogeneity of variance shows p < .05 (.001) which rejected the null hypothesis
that variances are equal. The post-hoc from the SPSS output is displayed in Table 17

Table 17
Test of Homogeneity of Variances of
Adherence Rate Based on Education

Levene
Statistic

df1

df2

Sig.

7.879

3

551

.000
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Bonferroni approach was employed to control for Type I error and a p value of
less than.05 was required for significance. From the SPSS output (Table 18), there were
statistically significant difference in adherence rate between those with tertiary education
and no education p < .05 (.002); tertiary education and primary education p < .05 (.001);
and tertiary education and secondary education p < .05 (.032). The partial ETA square
was less than 5% (.038). A 95% confidence interval was maintained throughout the
levels.
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Table 18
Multiple Comparisons for Dependent Variable: Adherence rate

Bonferroni
Mean

95% Confidence Interval

Difference (I(I) Education (J) Education J)

Std. Error Sig.

Lower Bound Upper Bound

None

Primary

Secondary

Tertiary

Primary

-.406

1.747

1.000

-5.03

4.22

Secondary

2.944

1.684

.486

-1.51

7.40

Tertiary

8.833*

2.406

.002

2.46

15.20

None

.406

1.747

1.000

-4.22

5.03

Secondary

3.349

1.308

.064

-.11

6.81

Tertiary

9.239*

2.160

.000

3.52

14.96

None

-2.944

1.684

.486

-7.40

1.51

Primary

-3.349

1.308

.064

-6.81

.11

Tertiary

5.890*

2.108

.032

.31

11.47

None

-8.833*

2.406

.002

-15.20

-2.46

Primary

-9.239*

2.160

.000

-14.96

-3.52

Secondary

-5.890*

2.108

.032

-11.47

-.31

*. The mean difference is significant at the 0.05 level.
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Employment. For employment, the result of the ANOVA analysis is displayed in
Table 19.
Tables 19
Test of Homogeneity of Variances of
Adherence Rate Based on Employment

Levene
Statistic

df1

df2

Sig.

8.408

3

544

.000

The mean difference to adherence rate between groups was statistically significant (F =
6.2, p <.001). Therefore, the null hypothesis that there was no statistically significant
mean difference between the groups was rejected (Tables 20).
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Table 20
ANOVA by Adherence Rate Based on Employment

Sum of
Squares

Df

Mean Square F

Sig.

Between groups

3331.662

3

1110.554

.000

Within groups

96619.212

544

177.609

Total

99950.874

547

6.253

There was a statistically significant mean difference between the two groups, so, a
post-hoc was used to explore if there was any variance within the group. The Levene’s
test for homogeneity of variance shows p less than .05 (.001) therefore, the null
hypothesis that variances are equal was rejected. Again, Bonferroni approach was
employed to control for Type I error and a p value of less than .05 was required for
significance. There were statistically significant differences in adherence rate between
farmers and unemployed with p value of less than .05 (.003) and between farmers and
employed, p of less than .05 (.022). The partial ETA square was less than 5% (.033). A
95% confidence interval was maintained throughout the levels.
Marital status. For marital status, the resulting p value of Levene’s test is .120 (p
>.05). The mean difference to adherence rate between groups was statistically nonsignificant (F = .657, NS .622, p >.05). Therefore, we failed to reject the null hypothesis
that there was no statistically significant mean difference between the groups.
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Distance. For a stratified distance to the hospital, the resulting p value of
Levene’s test is .084 (p >.05). The mean difference to adherence rate between groups was
statistically non-significant (F = 7.66, NS .622, p >.05). Therefore, we failed to reject the
null hypothesis that there was no statistically significant mean difference between the
groups.
Research Question 2
RQ2: What is the association between distance from treatment center and
adherence to ARV medicines among AYA?
Ho2: There is no statistically significant association between distance from
treatment center and adherence to ARV medicines among AYA
Ha2: There is statistically significant association between distance from treatment
center and adherence to ARV medicines among AYA
Correlation and bivariate analysis. Correlation test was performed between
adherence rate to ART and distance to the hospital and Spearman’s rho = -.088 with a
significant value of .048 (< .05), we therefore, reject the null hypothesis that said there
was no correlation between distance to the hospital and adherence rate to ART.
Correlation was also performed for all the metric-interval variables which include CD4
count, age of study population and years on ART. There was correlation between
adherence rate to ART and years on ART (rho = -.405, NS = .001, p <.05) and between
adherence rate and CD4 counts (rho = .122, NS = .011, p < .05). Correlation with the
other categorical predictors was carried out and there was statistically significant
correlation between adherence rate to ART and education (rho = -.166, NS = .001, p <
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.05); employment (rho = .257, NS = .001, p < .05); environment (rho =.165, NS = ,001, p
< .05); and marital status (rho =.104, NS = .015, p < .05). There was no statistically
significant correlation between adherence rate and gender (rho = -.012, NS = .765, p <
.05) and age (rho = .29, NS = .464, p > .05.
Linear regression. Linear regression was the statistical model that was used to
predict the relationship between adherence rate and distance to the hospital. The
statistical output from the linear regression shows R = .045, R2 = .002, B (unstandardized
coefficient) = -.011, NS = .312, p > .05. The result shows absence of statistically
significant linearity between adherence rate and distance to the hospital with 95%
confidence interval (-.033, .011) crossing the zero value. With the absence of linear
relationship with the outcome variable, there was no need to proceed with further
statistical tests.
Research Question 3
RQ3: What is the relationship between a high CD4 counts (> 500 cell/mm3) and
adherence to ART among AYA?
Ho3: There is no statistically significant relationship between a high CD4 counts
(> 500 cell/mm3) and adherence to ART among AYA.
Ha3: There is statistically significant relationship between a high CD4 counts (>
500 cell/mm3) and adherence to ART among AYA.
Correlation and bivariate analysis. Correlation test was performed between high
CD4 (≥ 500 cell/mm3) and adherence rate to ART and Pearson R = -.053, NS = .389, p
>.05. This shows there was no statistically significant correlation between the two
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variables. We therefore, failed to reject the null hypothesis that said there was no
statistically significant association between a high CD count (≥ 500 cell/mm3) and
adherence rate. In the absence of a correlation, there was no need for a regression
between a high CD4 counts (≥ 500 cell/mm3) and adherence rate.
A correlation test was also performed between a low CD4 counts (< 500
cell/mm3) adherence rate and there was correlation of Pearson R = .214, NS = .003, p <
.05. This showed a statistically significant correlation between the two variables. With
the correlation between adherence rate to ART and low CD4 (< 500 cell/mm3)
established, linear regression was used to predict the relationship between the two
variables. The statistical output shows R = .215, R2 = .046, B = 1.956, NS = .003, p < .05.
The result shows presence of statistically significant linearity between adherence rate and
CD4 (< 500 cell/mm3) with 95% confidence interval (.663, 3.249) not crossing the zero
value.
In order to test for a covariance between the outcome variable, high CD4 count (≥
500 cell/mm3), and other variables in the study, Pearson correlation was performed
between high CD4 count and employment status (R = .036, NS = .590, p > .5); years on
ART (R = .031, NS = .619, p > .05); environment ( R = .029, NS = .714, p >.05); marital
status ( R = .010, NS = .885, p >.05); distance ( R = -.076, NS = .219, p >.05); education
(R = -.076, NS = .255, p >.05); gender (R = -.065, NS = .297, p >.05); and age ( R = .007,
NS = .907, p >.05). The result shows no correlation with any of the variables.
In order to test for a difference in adherence rate between the two sub groups of
CD4 (≥ 500 cell/mm3 and < 500 cell/mm3), the independent t-test (two-tailed) was
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employed. Assumptions that must be taken into consideration while using t-statistics
include the variable having a discernible distribution that approximate normal (Field,
2013). The assumption of discernible distribution was met (i.e skew < |2| and kurtosis <
|9| (Schmider, E., Ziegler, M., Danay, E., Beyer, L., & Bühner, 2010). The mean
adherence rate to ART for those with low CD4 (< 500 cell/mm3) (N = 188) was M1 =
90.86 (SD1 = 14.763). Whereas, those with high CD4 (≥ 500 cell/mm3) (N = 250), M2 =
94.38 (SD2 = 11.373). Independent t-test was performed. Levene’s test for equality of
variance was examined. The key assumption in this test is that the variances for both
categories of patients are equal (Anderson et al., 2000). Therefore, we test for equal
variance assumed. The t-test result showed statistically significant difference in
adherence rate to ART between those with low CD4 (< 500 cell/mm3) and those with
high CD4 (≥ 500 cell/mm3), t (436) = -2.819, .005, p < .05. Therefore, we failed to accept
the null hypothesis that there is no significant difference in adherence rate to ART
between low and high CD4 counts among the study population.
The effect size of the difference in adherence between those with low and high
CD4 was estimated using Cohen’s d as follows:
Cohen’s d = (M 2 - M 1)/SDpooled
SDpooled = √(SD12 + SD22)/2
M 1 = Mean difference of adherence for those with CD4 < 500 cells/mm3 = 90.86
M 2 = Mean difference of adherence for those with CD4 (≥ 500 cell/mm3) = 94.38
SD1 = Standard deviation for adherence for those with CD4 (< 500 cells/mm3) = 14.763
SD2 = Standard deviation for adherence for those with CD4 (≥ 500 cell/mm3) = 11.373
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d = .378. This is approximately .38.
Summary
In Chapter 4, I examined the difference in adherence rate to ART based on
location (urban and rural) among AYA including the effect size of the difference that was
found. The statistical difference in adherence rate among several variables was also tested
and these variables included age of patients; gender; number of years on ART, CD4
counts, distance from patient’s home to the ART center; level of education, marital
status; and employment status. Where differences existed, the effect size of the difference
was estimated using Cohen’s d. The association between adherence rate to ART and
distance was explored in the chapter. In addition, the relationship between a high CD4
count described as CD4 ≥ 500 cells/mm3 and adherence rate to ART was explored.
The results show differences in adherence rate to ART between urban and rural
dwellers. There was difference in adherence rate between farmers and unemployed;
farmers and employed. Those with tertiary level of education also had difference in
adherence with those with no education or primary education or secondary education.
Difference in adherence was also observed between those living at most 50 kilometers
away from the ART center and those living farther than 50 kilometers away from the
ART center. While correlation exists between distance to the ART center and adherence
rate, there was absence of linearity between the two variables. There was no association
between CD4 that was at least 500 cells/mm3 and adherence rate. However, CD4 that was
less than 500 cells/mm3 was linearly related to adherence rate. The result also shows that
there was no correlation between CD4 that was at least 500 cells/mm3 and age of patients;
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gender; number of years on ART, distance from patient’s home to the ART center; level
of education, marital status; and employment status.
In Chapter 5, the results in Chapter 4 was reviewed and related to what is obtained
in current literature. I discussed findings from the result alongside social implication for
change. I also looked at the appropriateness of applying the result in the larger
population. I equally provided insight into the limitations of the study and offered
recommendations for future research.
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Chapter 5: Discussion, Conclusions and Implications
Introduction
Adherence to ART among AYAs is very important in the management of HIV as
the AYA stage is the transition to full adulthood. However, suboptimal adherence to
ARV has been reported among AYAs (Xu, Munir, Kanabkaew, & Le Coeur, 2017b).
Involvement in risky sexual behavior with little interest in engaging appropriate health
services is not uncommon for individuals in this age bracket. World-wide, only 62% of
AYAs on ART adhere to ARV medicines (S.-H. Kim et al., 2014). My specific goals in
this quantitative cross-sectional study were (a) to explore the difference in adherence to
ART among AYAs accessing care in the same treatment center but resident in different
rural and urban settings, (b) to explore the association between adherence of AYAs
stratified by distance from the treatment center, and (c) to determine the nature of the
relationship between adherence and CD4 counts after an AYA attained a CD4 cell count
greater than 500 cell/ mm3.
Secondary data was obtained on patients who accessed HIV care and treatment
from FMC Makurdi, Nigeria for the period between 2010 and 2016. Data obtained
included pharmacy refill records, distance from patient’s home to the ART center, CD4
counts, and environment (urban or rural). Demographic variables that were also collected
included age of patients, number of years on ART, employment status, level of education,
and marital status. Various statistical tests were carried out using SPSS version 24. I
carried out independent t tests to assess the difference in adherence rate to ART patients
in urban and rural areas accessing health care at the FMC Makurdi. I found a statistically
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significant difference in adherence rate to ART between the two groups at t (424) = 3.280, .001, p < .05. Cohen’s d of the effect size was .5. A statistically significant
difference in adherence rate was also observed between those who lived at most 50
kilometers away from the hospital and those that lived more than 50 kilometers away
from the hospital, t (509) = -2.37, .018, p < .05 with Cohen’s d value of 0.04. In addition,
there was a statistically significant difference in adherence rate between those with CD4
counts of at least 500 cell/mm3 and those with less than 500 cells/mm3, t (436) = -2.819,
.005, p < .05 with a Cohen’s d value of .4. A simple linear regression between CD4 count
of less than 500 cells/mm3 and adherence rate to ART shows a significant regression (F
(1,184) = 8.907, p = .003) with an R and R2 of .215 and .046 respectively.
Interpretation of Findings
The dearth of studies on the differences in ART adherence rates among AYAs in
Nigeria based on environment (urban or rural) made my research necessary to extend the
body of knowledge in this area of HIV management with ART. I assessed the difference
in ART adherence rates among AYAs from the FMC Makurdi, Benue Sate, Nigeria and
found a mean adherence rate of 94% and 89% for patients who resided in rural and urban
environment, respectively. The difference was statistically significant: t (424) = -3.280,
.001, p < .05. This agrees with Oku et al .(2013) in their study of adherence to ART by
people living in Calabar (a major city in Nigeria) and accessing care in University of
Calabar Teaching Hospital and those coming from rural areas where there was a
difference between the two groups with the latter having a better adherence to ART.
Suffice to say the Oku et al .(2013) study was a study based on patient self-report while
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my study was based on pharmacy refill records. My findings also align with those in a
study conducted in another part of Africa, the Republic of Togo (Hudelson & Cluver,
2015). This cross-sectional study of 291 people living with HIV AIDS ages 10 – 19
years, at the regional hospital of Sokode showed that those residing in rural areas had a
comparatively better adherence rate than those in the urban areas (81%; p value less than
.05). According to Hudelson and Cluver (2015) who carried out the systematic study,
environment (urban versus rural) could have impact on adherence to ART. The effect size
of the difference in my study has a Cohen’s d value of .5 (Sullivan & Feinn, 2012). This
implies the mean variance between the adherence rates of patients in rural and urban
setting is of moderate effect. My study finding indicated that the AYAs in Benue State
who reside in the rural area are better in adherence to ART than their counterpart in the
urban areas.
For the RQ 2, I attempted to explore the association between distance to the ART
treatment center and adherence to ART. My findings disconfirm those in studies by
Eyassu et al. (2016) in South Africa and Chineke (2015) and Falang et al. (2012) in
Nigeria. These earlier studies indicated that distance to treatment center was associated
with adherence, and that those father from treatment center were less adherent. There was
no association between distance and ART adherence rate except when distance was
categorized into “near” and “far.” It is imperative to mention that previous studies never
mentioned the specific distances that were considered far or near. The mean adherence
rate for AYA who lived within a 50-kilometer radius (90.66%) was different from those
who lived beyond a 50-kilometer radius (93.53%). Though the difference was observed

108
to be statistically significant ( t (509) = -2.37, .018, p < .05), the Cohen’s d value of 0.044
shows the effect size of the difference is trivial (Sullivan & Feinn, 2012).
I categorized distance into at most 50 kilometers and greater than 50 kilometers as
“near” and “far” respectively to see if there was difference between those groups. It is
instructive to note that because Makurdi metropolis is only about 20-kilometers in radius,
those considered “near” are not exclusively residents in the Makurdi metropolis. The
finding was not expected under normal circumstances because people living near a health
facility are naturally expected to be more adherent in keeping to their pharmacy refills
appointments. My research finding showed that factors that influence adherence could be
multifaceted and not just limited to proximity to the ART center. However, when the
distance was stratified into 0-50, 51- 100, 101-150, 151 – 200, 201 – 250, 251 -300, and
301 -350 kilometers, there was no correlation with adherence rate. Also, there was
absence of statistically significant linearity between adherence rate and distance to the
hospital (R = .045, R2 = .002, B (unstandardized coefficient) = -.011, NS = .312, p > .05)
with 95% confidence interval (-.033, .011) crossing the zero value. This confirms
Carlucci et al. (2008) who carried out a study in South Africa and concluded distance
could not predict adherence to ART.
In my RQ 4, I assessed the difference in ART adherence rates between individuals
with a CD4 count of 500 cells/mm3 and greater, and individuals with a CD4 count under
500 cells/mm3. The mean adherence rate for the groups was 94.38% and 90.86%
respectively. This was found to be a statistically significant difference: t (436) = -2.819,
.005, p < .05 with a Cohen’s d value of .38. (i.e., approximately .4). This shows the effect
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size of the difference was moderate (Sullivan & Feinn, 2012). My study did not show any
correlation between a high CD4 (≥ 500 cell/mm3) and ART adherence rate (R = -.053,
NS = .389, p >.05). This finding confirms those of Nyogea et al. (2015) who carried out a
study on determinants of adherence among children and adolescents in Tanzania but
found no association between adherence and CD4 counts. On the other hand, low CD4 of
less than 500 cells/mm3 correlated with adherence rate R = .215, R2 = .046, B = 1.956, NS
= .003, p < .05. This means that as adherence increases, the CD4 count would continue to
increase until it reaches 500 cell/mm3, at which point there will be no more correlation
between the two variables. This aspect of the result disconfirms Nyogea et al. (2015). My
finding is not surprising because a plethora of other studies have linked adherence rate to
CD4 counts (Achappa et al., 2013; Alleemudder, Tai, Goyal, & Pati, 2014; Boussari et
al., 2015; Lamiraud et al, 2012; Rai et al., 2013; Reda & Biadgilign, 2012). However,
what is new is that my research shows the correlation stops at a CD4 of 500 cells/mm3.
Further research is needed to understand the absence of correlation at a CD4 count of 500
cells/mm3 and over.
Also, at both CD4 levels (≥ 500 cells/mm3 and < 500 cells/mm3), the mean
adherence rate was deemed good adherence (≥ 85%). Since both levels of CD4 counts
have a good adherence, it suggests adherence might not be the only factor in an improved
CD4 counts by patients on ART. For the patients (N = 656) in the analysis, 38.1% (n =
250) had counts greater than or equal to 500 cells/mm3, while 28.7% had a count below
500 cells/mm3. A higher CD4 counts is associated with low risk of opportunistic
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infections (Young, 2012). This implies that many of the AYA on ART in Benue State,
Nigeria are doing well.
Other findings from the study involve the relationship between adherence and
other variables. Difference in adherence rate was statistically significant between
different levels of education (F = 7.2; p < .05). Those with no education had a mean
adherence rate of 94.15%, compared with 85.32% for those with tertiary education (p =
.002). The mean adherence rate for those with primary level of education was 94.56%,
which was found to be statistically significantly higher than those with tertiary level of
education (p = .001). This shows that adherence to ART is not dependent on level of
education, but the reason for this seeming aberration is not clear. Pennap et al. (2013)
concluded that educational level was a positive predictor of adherence. The results from
other studies are equally contradictory. For example, in a study of medication adherence
to antihypertensive medicines in the United States, the result varies by gender. Among
males, those with below high school education had a higher adherence compare to those
with higher school and above, while the reverse was the case with females (Braverman &
Dedier, 2009). My study shows no statistically significant difference in adherence
between those with primary school (94.56%) and no education (94.15%), with both
having the highest adherence rate comparatively. This does not confirm the expectation
that the higher the level of education, the better the adherence to medication.
There was a slight difference in adherence rate between females (92.06%) and
males (91.94%), but the difference was not statistically significant t (650) = .066, .947, p
>.05. The findings confirm those of Akahara et al.(2017) and Pennap et al. (2013) who
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both studied adherence among patients in Nigeria and also found no significant difference
in adherence by gender. However, my findings are at variance with those of Falang et al.
(2012) who found that adherence was strongly associated with gender among ART
patients in Nigeria.
With respect to age of patient, there was a mean difference in adherence rate
between ages 15 -19 years (93%) and ages 20 -24 years (92%). However, the mean
difference in adherence rate was not statistically significant t (518) = .304, NS = .761, p >
.05). The finding is not surprising as adherence rate in the age bracket have been found to
be fairly the same (Kim et al., 2014; Maskew et al., 2016; Shaw & Amico, 2016). It
shows the AYAs from Benue State, Nigeria are not different from their peers in other
parts of the world when it comes to impact of age on adherence to ART.
There was a statistically significant difference in the mean adherence rates based
on employment status (F = 6.2, p <.001). The mean adherence rate for farmers (95.35%)
was statistically significantly different from that of the unemployed (90.95%) with p =
.003. The mean adherence rate was also higher among famers compare to the employed
(84.58%) with p =.022. The adherence rate for business persons was roughly the same
with the unemployed, 90.88%. The study result shows that farmers have the highest
adherence rate. This is striking as it was observed earlier that those with no education had
higher adherence rate compare to those with secondary and tertiary education. So, the
findings confirm what is expected since most of the farmers in Nigeria are illiterates
(Dudafa, 2013). However, the partial ETA square of .033 with a 95% confidence interval

112
was maintained throughout the levels. The partial ETA square was .033 which implies
the effect size is less than 5%, very small.
Falang et al. (2012) in their study found an association between adherence rate
and employment but the association was not found to be statistically significant. The
employed category had a smaller mean adherence rate. It could be that seeking
permission from employer to keep up with routine pharmacy refill appointment was a
challenge. This is possible especially in an environment where there is a high level of
stigma to the HIV virus. The unemployed have an adherence rate comparable to those in
business and this is surprising because typical unemployed AYA is an economically a
dependent so one would expect cost of transportation to ART to pose a hinderance
according to Groh et al. (2011). The finding suggests that when it comes to keeping up
with pharmacy re-fill appointments for ART, the unemployed have adherence rate higher
than the employed and almost comparable with business people. The result of the study
shows there was no difference in adherence rate based on marital status (F = .657, NS
.622, p >.05). However, in a related study of adherence to ART among pregnant women
in Nigeria, marital status was found to be strongly related to adherence (Ekama et al.,
2012).
The first mean CD4 counts for the study population irrespective of their distance;
environment; level of education; employment status; marital status; age; and gender was
320 cells/mm3. The mean CD4 value became 400 cells/mm3 in the second year; 418
cells/mm3 in the third year; 454 cells/mm3 in the fourth year; 504 cells/mm3 in the fifth
year; and 568 cells/mm3 in the sixth year respectively. This shows a continuous
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improvement in the health of the patients. The overall findings support the concept of the
TTM, the theoretical framework which the study was premised. The protocol for HIV
treatment in Nigeria is to test and treat as many as are eligible. For the ART naïve
patients, ARV adherence counseling (pre-contemplation and contemplation stages)
precedes enrolment on the ARV medicines and patients are assumed to be in the
preparation or action stage of the TTM (Prochaska & Velicer, 1997) at the time of
commencing ART. The expectation at the stage is for a steady rise in CD4 count level
that reflect a high adherence; an acceptance of the new health style. The consecutive
increase in the CD4 counts for the AYA in the study is in line with the theoretical
framework.
Limitations of the Study
The scope of the study was about exploring adherence to ART among AYA with
respect to where patient resided, proximity to ART center among others. The adequate
sample size and power of the study sample notwithstanding, findings cannot be
generalized to the entire Nigeria because it is a cross sectional study. Also, because of the
nature of the study, I could not explore the role of other factors in influencing the study
outcome (adherence to ART) such as stigma; presence or absence of social support; and
ARV counseling prior to commencement of ART. Data composition was also a limitation
as sample was only from the FMC Makurdi ART center and attitude of health care
providers is known to influence adherence rate (Ankrah et al., 2016). Finally, the
purposeful sample selection means not all patients accessing care in the FMC Makurdi
stood equal chance of been selected for the study.
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Recommendations
Though the difference in adherence rate between ‘far’ (> 50 kilometers) and
‘near’ ≥ 50 kilometers) clients was observed to be statistically significant, the effect size
of the difference was trivial. A further study using a qualitative approach is
recommended. The primary data for the study was not collected by the researcher as a
result many variables that could have shed light such as peer-pressure, social support,
religion, culture and stigma were not captured. These would have provided a better
understanding of how the independent variables in the study influence the study outcome,
adherence rate to ART. In the light of that, I recommend a more in-depth study among
AYA using a qualitative approach like a focused group discussion where other factors
such as the role of peer pressure, religion and social support in adherence rate to ART
would be explored. Suffice to say that it will be expensive, however, my study would
serve as the baseline for such proposed study.
In addition, an interview of AYA on ART who reside in both rural and urban
areas would elucidate more knowledge on other factors that influence their adherence
rate. Knowing what AYA in the FMC Makurdi think about the isolation of the HIV clinic
building called the ‘Riverside Clinic’ from the main FMC Makurdi will be important –
whether it impacts adherence rate. This is because stigmatization is still a serious issue in
the Nigerian society. Future research should also incorporate data from more than a
single health facility in order to explore the role attitude of health care providers play in
adherence to ART among AYA. There was correlation of CD4 cell counts to adherence
rate only at a CD4 of <500 cells/mm3. Further research is needed to understand why
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beyond 500 cells/mm3, there is no more a correlation. This will provide basis for review
of the current continuous adherence counselling sessions for all patients irrespective of
their CD4 levels.
Implication for Positive Social Change
My findings have various implications for positive social change. The findings
have suggested a correlation between adherence to ART and a low CD4 counts of less
than 500 cells/mm3; a difference in adherence rates between ‘near’ and ‘far’ kilometers;
and difference in adherence rates based on environment (urban and rural) among the
AYAs in Benue State, Nigeria. To the best of my knowledge, no similar study has been
carried out on these variables among AYAs in Nigeria.
Among the business owners, the employed, the unemployed and the farmers, the
employed clients had the lowest adherence rate from the research findings.
Stigmatization, humiliation and discrimination are still a challenge in Nigeria that makes
HIV positive people not willing to disclose their status in their working environment.
This might constitute a challenge in getting official approvals to keep a date with the
routine and regular clinical appointments for those on ART. In the light of the findings
from my research, the governments (Federal, State and Local) should ensure the AntiDiscrimination Act 2014 which makes it illegal to discriminate against people based on
their HIV status (Guardian, 2015) is not only on pages of papers but fully implemented.
The impression that educated people because of their education are better
adherent was disconfirmed by my study. Based on the findings, adherence counselors
would need to evolve adherence counselling strategies that focus equally on both
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educated and less or no educated clients. Also, the call for government to initiate a policy
that makes every health center an HIV treatment center for the purpose of improved
adherence is not confirmed by my research. Since I found finds a lower adherence rate
for clients within a radius of ≤ 50-kilometer to the ART center, making ART center
within 50-kilometer radius would reduce other attendant costs such as transportation for
patients but unlikely to improved adherence.
Findings from my study could have applicability on other health care services that
are carried out in designated places and based on clinical appointments like HIV. These
would include nephrology, oncology and diabetes. Clients living within 50-kilometer
radius to a health facility are not necessary going to be more adherent to their clinical
appointments than those farther away. Rather, those residents more than 50 kilometers
away are likely to be better adherent. As a result, during adherence counselling sessions,
additional strategies should be employed to encourage adherence amongst those living
‘near’.
Because high adherence rate below 500 cells /mm3 is positively relate with
adherence, during counselling sessions, adherence counselors could focus mostly on
those with poor or suboptimal levels of adherence (< 85 %) to adopt strategies to improve
their adherence rate in order to see a possible increase in CD4 counts. A higher
proportion of those in the higher level of socio-economic stratification in Nigeria is found
in urban areas compare to rural areas. As such, emphasis during adherence counselling
sessions is usually more on people from the rural areas. This might have contributed in
making them have a better adherence rate than those in urban areas. But the implication
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of the findings in practice is that all clients should be equally counselled. In overall, the
IPs of HIV programs would make use of these findings to review their HIV adherence
counseling curriculum as some of the presumptions as listed above were not confirmed
by my research.
Conclusion
The findings from the study showed: (a) the AYAs on ART in the FMC Makurdi
who resided in rural areas had a better adherence compared to those who resided in urban
areas (b) the AYAs on ART in the FMC Makurdi who lived greater than 50 kilometers
away from the ART center had a better adherence to ART than those within a radius of
50 kilometers (c) CD4 counts was positively related to the adherence rate until when the
counts reached 500 cells/mm3. These findings have contributed to the existing knowledge
on factors that influence adherence rate to ART among AYA in Benue State, Nigeria. In
the light of the research findings, IPs that are responsible in working in partnership with
governments in Nigeria to implement HIV management programs in various health
facilities need to devise new strategies that focus on those who are proximal to ART
center to improve their adherence to ART since they comparatively have a lower
adherence rate. The comparatively lowest adherence rate by clients who were employed
calls for an approach that would help improve their adherence rate (meeting up with
pharmacy refill appointments). A suggested approach would be an advocacy to executive
arms of the government to start enforcing the Anti-Discrimination Act 2014 which makes
it illegal to discriminate against people based on their HIV status. This would make
people living with HIV AIDS to freely to talk to their employers about their HIV status
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and also apply for official approvals to attend to their clinical appointments including
pharmacy refills.
AYA in Benue State have a very good adherence as the mean adherence for the
study was 92%. This should be sustained since high adherence rate relates positively with
CD4 count when the CD4 has not reached 500 cells/mm3 knowing very well that high
CD4 counts reduces risk of infection. Adherence to ART is one of the key indicators for a
successful management of HIV as it reduces morbidity, mortality and also helps
minimize transmission of the virus. While there is a plethora of ARV cocktail in the
management of HIV, these drug combinations give the desired therapeutic result only
when patients are adherent to the regimes. In order to achieve the vision ‘90-90-90’ by
UNAIDS which aims to end AIDS epidemic generation (UNAIDS, 2016; UNAIDS
2014), those who are on ART must be adherent.
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